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Introduction
1. Introduction
1.1. Gastrointestinal cancer
1.1.1. Introduction
According to the World Health Organisation (WHO), in 2012, there were 
8.2 million people worldwide who died from cancer. It is estimated that the 
number will even rise to 13.1 million in 2030.
Of 8.2 million deaths in 2008, liver cancer accounts for approximately 
746,000, colorectal cancer for 694,000 and gallbladder cancer for 143,000 
deaths (Ferlay et al, 2012).
Figure 1.1. Cancer frequency in both sexes. Taken from (Ferlay et al, 2012).
1.1.2. Hepatocellular carcinoma
Of all cancer deaths world wide, liver cancer is the second leading cause
(Ferlay, 2012) and numbers are constantly increasing (Maluccio & Covey, 
2012).
There are many types of liver cancer, of which hepatocellular carcinoma 
(HCC) accounts for up to 70 - 85 % of all liver cancers worldwide (Perz et al, 
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2006). Major risk factors are aflatoxin B1 exposure (Ming et al, 2002), hepatitis 
B virus (HBV) and hepatitis C virus (HCV) infections, to which 78 % of global 
HCC incidences are attributable (Perz et al, 2006). This also explains high rates
of HCC in parts of Asia and Africa, where prevalences of chronic hepatitis B 
infections of up to 8 % are quite common (Jemal et al, 2011). In Western 
countries, which are at a rather low risk for HCC, factors such as alcohol-related
cirrhosis and nonalcoholic steatohepatitis (NASH) mainly contribute to the 
development of HCCs (Jemal et al, 2011; Maluccio & Covey, 2012). 
The only curative options for HCC still remain liver transplantation and 
surgical resection, both in quite early stages of the disease. Patients who meet 
with Milan criteria (basically HCC with one nodule < 5 cm or up to 3 with each < 
3 cm) for liver transplantation can experience a 4-year overall survival of 85 % 
(Mazzaferro et al, 1996). However, as HCCs are mostly advanced and 
disseminated when diagnosed, curative treatment is mostly not possible. The 
current ten-year-survival rate after resection is 7.2 % (Gluer et al, 2012). With 
the introduction of a first systemic therapy with Sorafenib, median survival could
be prolonged by 3 months (Llovet et al, 2008), but due to development of 
multidrug resistances, “conventional” chemotherapy is only temporarily effective
(Li et al, 2001). These circumstances are also reflected in the almost identical 
numbers of incidence and mortality, indicating that most HCC patients cannot 
be “rescued” and then die of their disease (Ferlay et al, 2012; Maluccio & 
Covey, 2012).
1.1.3. Cholangiocarcinoma
Cholangiocarcinoma is an adenocarcinoma of the extra- and intrahepatic
bile ducts (Lau & Lau, 2012; Pattanathien et al, 2013). Compared to other 
malignancies, numbers of Cholangiocarcinoma incidences are relatively low. 
However, high rates are found in parts of Eastern Asia and especially Thailand, 
which appears to be mainly due to infections with liver flukes (Shin et al, 2010). 
Chronic biliary inflammation in general is considered as a risk factor including 
primary sclerosing cholangitis (Claessen et al, 2009), hepatolithiasis and bile-
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duct cysts (Tyson & El-Serag, 2011). In general, therapy of Cholangiocarcinoma
is known to be highly difficult and challenging. Total surgical excision is still the 
only curative approach, since Cholangiocarcinomas hardly respond to neither 
radiation nor chemotherapy. If not resectable or already metastasized, patients 
are treated in a palliative manner (Lau & Lau, 2012). One study from Thailand 
provides median survival data of 15 months and 5-year survival rates of 10.8 % 
after surgical treatment (Pattanathien et al, 2013).
1.1.4. Colorectal carcinoma
Colorectal cancer (CRC) is the fourth leading cause of cancer deaths 
worldwide (Ferlay et al, 2012). Incidences are higher in industrialized countries 
and in men. It is assumed to be mainly due to dietary factors (red meat, alcohol,
little intake of fibre), obesity, physical inactivity, diabetes mellitus and smoking 
(Jemal et al, 2011). In contrast, preventive screening programs for early 
detection of premalignant adenomas and localized cancer were shown to 
significantly decrease incidence and mortality of colorectal cancer (Atkin et al, 
2010).
Surgery remains the basis of curative approaches and is combined, if 
necessary, with radiation and chemotherapy. If possible, total resection of the 
tumor should be aspired. Relapse after surgery mostly becomes manifest in 
liver and lung metastases (Cunningham et al, 2010). According to the 
EUROCARE-4 data between 2000 and 2002, colorectal cancer patients in 
Europe have a 5-year survival rate of 56.2 % (Verdecchia et al, 2007).
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1.2. 5-FU and latest therapeutical state of the art
1.2.1. Antineoplastic therapy
Today's therapeutic options for cancer basically consist of chemotherapy,
surgical resection, radiation therapy as well as novel biological anti-cancer 
therapies. 
Chemotherapy has its origin in World War I and II, when autopsies of 
people poisoned by mustard gas revealed severe bone marrow depressions. 
Further investigations showed that the effect correlated with the proliferative 
activity of tissues. In 1942, its antineoplastic potential was discovered and 
mustard gas derivatives were thus introduced as first chemotherapeutic drugs 
(Papac, 2001).
Development of other alkylating drugs (e.g. cyclophosphamide) followed and 
with the finding of aminopterin as a folic acid antagonist, therapy with anti-
metabolites was initiated (Farber & Diamond, 1948). Since that time, the search
for new and efficient anti-neoplastic drugs has become a major field in tumor 
therapy.
However, there are severe disadvantages of chemotherapy: as already 
mentioned the anti-tumor properties of chemotherapy depend on the 
proliferative activity of cells. High proliferation rates are not only a characteristic 
of cancer cells, but also of hematopoietic cells and many epithelial tissues, 
which explains common toxic side effects of chemotherapy. This results in a 
dose-limiting toxicity and eventually in a less effective therapy (Moolten et al, 
1990).
Furthermore, tumors often show decreasing response to drugs during therapy 
and acquire resistances. Cancer stem cells, which are hardly affected by 
common therapies, are thought to be responsible for the initiation of resistance 
and relapse after initially successful therapy (Cripe et al, 2009). Moreover, 
tumor cells develop mechanisms to inactivate drugs or induce production of 
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membrane transporters, which either take up less or export more of the 
chemotherapeutic drug (Zahreddine & Borden, 2013).
Taken together, despite continuous improvements in cancer therapy and 
prolonged survival of treated patients, complete remissions and cure of cancer 
are rare and anti-cancer drugs, which selectively affect tumor cells whilst 
sparing normal cells, are still being searched extensively.
1.2.2. 5-FU
5-fluorouracil (5-FU) is an anti-cancer drug, which has been introduced in
1957 by Charles Heidelberger (Heidelberger et al, 1957). Since that time, it has 
been used especially for palliation, treatment of metastasized breast and colon 
cancer (Heidelberger & Ansfield, 1963) and also for genito-urinary, gastric, liver,
pancreas and head and neck cancer (Kanai et al, 1998). 
 
 
Figure 1.2. Chemical structure of Uracil (left) and 5-Fluorouracil/5-FU (right). Taken and 
modified from (Vermes et al, 2000).
5-FU is a pyrimidine anti-metabolite, as it very much resembles the 
pyrimidine uracil, but is fluorine-substituted at position 5. In the pyrimidine ring 
of thymine, to which uracil is converted by thymidylate synthase (TS), there is a 
methyl group at position 5. Conversion of uracil to thymine by TS was therefore 
supposed to be blocked (Heidelberger et al, 1957), thus inhibiting DNA 
synthesis, as TS is the only source of newly produced thymidine (Danenberg, 
1977). 
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In fact, the toxic effect is directed to both, DNA (Cohen et al, 1958; 
Heidelberger & Ansfield, 1963) and RNA (Cory et al, 1979; Glazer & Peale, 
1979; Glazer & Lloyd, 1982; Piper & Fox, 1982). The mechanism of action looks
as follows: in the first step, 5-FU is converted to 5-fluorouridine-5'-mono-
phosphate (5-FUMP). This happens either directly by orotate phosphoribosyl-
transferase (OPRT) or in two steps by uridine phosphorylase to intermediate 5-
fluoro uridine and by uridine kinase to 5-FUMP (Cohen et al, 1958; Piper & Fox,
1982).
In the second step, 5-FUMP is further metabolized by cellular nucleotide 
kinases to 5-fluorouridine-5'-diphosphate (5-FUDP). 5-FUDP may then be 
toxified to the final, cytotoxic metabolites by (i) further phosphorylation by 
nucleotide kinases to 5-fluorouridine-5'-triphosphate (5-FUTP), which directly 
interferes with production and function of all RNA classes (Wilkinson & Pitot, 
1973; Glazer & Peale, 1979; Glazer & Lloyd, 1982). 5-FUDP can also be 
converted by (ii) ribonucleotide reductase to 5-fluoro-2'-deoxyuridine-5'-
diphosphate (5-FdUDP) and then to 5-FdUMP which irreversibly suppresses TS
and therefore DNA synthesis (Cohen et al, 1958). A third possibility is that (iii) 5-
FdUDP is converted to 5-FdUTP, which is incorporated into DNA and hence 
damages the DNA. Extensive base-excision repair causes DNA fragmentation 
and therefore cell death (Thorn et al, 2011).
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Figure 1.3 5-FU activation and mechanisms of action. 
5-FU = 5-fluorouracil, 5-FUMP = 5-fluorouridine 5‘ monophosphate, 5-FUDP = 5-fluorouridine 5‘ 
diphosphate, 5-FUTP = 5-fluorouridine 5‘ triphosphate, NK = nucleotide kinase, OPRT = orotate
phosphoribosyltransferase, RNR = ribonucleotide reductase, TS = thymidylate synthase, UK = 
uridine kinase, UP = uridine phosphorylase. Figure based on (Cory et al, 1979; Piper & Fox, 
1982; Valeriote & Santelli, 1984; Thorn et al, 2011).
However, as 5-FU is an anti-metabolite, its effect at concentrations that 
are safe to administer systemically is dependent on cell proliferation. It is 
therefore assumed, that insufficient therapy with 5-FU is due to the fact that only
10 % of all carcinoma cells are cycling at the same time (Akbulut et al, 2004). 
Doses to also kill slowly or non-proliferating cells would cause unacceptable 
toxic effects.
Such toxic side effects depend on the method of administration 
(continuous therapy, daily or weekly bolus therapy) and are typically myelo-
suppression with neutropenia, stomatitis, mucositis, diarrhea, dermatitis and 
conjunctivitis (Weh et al, 1994; de Gramont et al, 1997).
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1.3. Oncolytic virotherapy
Oncolytic virotherapy is a new approach to treat cancer, which is 
currently under preclinical and clinical investigation. The idea is basically that a 
replication-competent virus selectively infects tumor cells, replicates within them
to produce progenies and eventually destroys its host cells. Ideally, those 
viruses do not affect untransformed, non-malignant tissues and have therefore 
limited or even no toxic side effects. 
In the following chapter, the discovery of oncolytic viruses, their principle 
of operation, advantages and disadvantages as well as further improvements to
enhance the oncolytic effect will be explained.
1.3.1. History and finding of oncolytic viruses
The discovery of viruses as novel cancer therapeutics was rather 
coincidental. There are numerous case reports about tumor patients who 
occasionally developed a viral infection which led to an (although mostly partial)
remission of their neoplastic malignancy (Kelly & Russell, 2007). Regressing 
leukaemias (Gross, 1971; Pasquinucci, 1971), Burkitt’s lymphomas (Bluming & 
Ziegler, 1971), and Hodgkin’s diseases (Mota, 1973) after infections with wild-
type measles virus (MeV) are only few examples. Similar observations were 
made with cases of acute leukaemia after glandular fever infections (Taylor, 
1953) and chicken pox (Moore, 1954). However, these reports were not limited 
to natural infections only, but also attenuated viruses used for vaccinations were
able to cause tumor regressions. Repeated smallpox vaccination caused a 
complete remission for 3 years in a patient suffering from untreated chronic 
lymphocytic leukaemia (Hansen & Libnoch, 1978). A case of cervix cancer and 
few of melanoma were noted to improve after rabies vaccination (Moore, 1954).
Subsequently, viruses and their vaccines were investigated as totally 
new approaches for the therapy of cancer. Although some of those case reports
were already presented much earlier, oncolytic virotherapy with wild-type 
viruses started in the 1950s. Further developments of the advanced viro-
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therapeutic agents, being derived from genetic engineering, began in the 1990s 
(Liu et al, 2007).
1.3.2. Advantages and disadvantages
Broadening the options for the treatment of cancer, oncolytic viruses 
have some advantages over common therapies. First of all, viruses were 
evolutionarily adapted to efficiently infect and replicate within their host cells. 
They exploit the host to produce further progenies, which in turn are able to 
infect neighbouring cells (Msaouel et al, 2009). Secondly, oncolytic viruses 
selectively infect and replicate in tumor cells, leading to apoptosis or infection-
related lysis. Consequently, non-transformed cells are not affected and 
systemic toxicity is therefore limited (Li et al, 2001; Liu et al, 2007). Thirdly, 
even tumor cells being apoptosis- or chemotherapy-resistant can be killed by 
viruses, demonstrating that there is no cross-resistance (Coukos et al, 2000; 
Khuri et al, 2000; Reid et al, 2002; Richard et al, 2007; Cattaneo et al, 2008). 
Also tumor stem cells, which are hardly affected by common chemothera-
peutics, show susceptibility towards virotherapy (Cripe et al, 2009; Mahller et al,
2009). Beyond that, oncolytic viruses have been proved to be safe in all clinical 
trials that have been performed to date, generally having caused not more than 
any flu-like symptoms (Khuri et al, 2000; Kirn, 2001; Reid et al, 2002; 
Heinzerling et al, 2005; Liu et al, 2007; Galanis et al, 2010). Overall, safety has 
already been affirmed for at least six different virus species, administered to 
over 800 patients (Liu & Kirn, 2008).
However, there are also disadvantages of this novel therapeutic 
approach. The immune system not only supports oncolysis by identifying and 
killing infected cells, but also recognizes the viral particles as foreign and hence 
eliminates a major percentage before they can efficiently infect the tumor 
(Breitbach et al, 2007; Cattaneo et al, 2008; Liu & Kirn, 2008; White et al, 2008; 
Prestwich et al, 2009). In fact, relatively low antibody titers are already able to 
hugely neutralize the systemically delivered viruses (Ong et al, 2007). Repeated
applications induce increasing titers of neutralizing antibodies and thus lessen 
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the effect (White et al, 2008). Even alternatives to circumventing intravenous 
application by, for example, directly injecting the viruses into the tumor, are 
insufficient (Russell et al, 2012). But not only antibodies, complement or 
phagocytes hinder the delivery, there are also mechanic barriers like fibrosis, 
necrosis and elevated interstitial pressure within the tumor complicating the 
infection (Jain, 2001). The reticuloendothelial system in organs like spleen and 
liver is also responsible for virus clearance (Prestwich et al, 2008; Russell et al, 
2012). 
Despite the promising oncolytic potency, a single therapy won’t be sufficient and
has therefore to be further investigated and combined with other therapeutic 
options (Liu et al, 2007; Cattaneo et al, 2008).
1.3.2. Mechanism of oncolysis
Tumor cells are characterized by their genetic mutations and genomic 
instability. Proliferation is associated with further genetic alterations and defects 
and may, by chance, result in new capabilities and growth advantage. However,
those mutations are not directional and cancer cells not only acquire new 
features, but also lose preexisting abilities (Hanahan & Weinberg, 2011).
One example is mutation within interferon (IFN) mediated pathways 
(Colamonici et al, 1992; Sun et al, 1998), which normally protect cells from viral 
infections, inhibit cellular proliferation and activate apoptotic signals (Clemens &
McNurlan, 1985; Stark et al, 1998). Being resistant towards those signals, 
cancer cells are protected from IFN mediated clearance (Stojdl et al, 2000; Naik
& Russell, 2009; Lech & Russell, 2010). At the same time however, they 
become susceptible to viral infections when losing their innate antiviral 
protection, whilst untransformed cells turn into an antiviral state. This accounts, 
amongst other reasons, for the cancer-selectivity of oncolytic viruses (Stojdl et 
al, 2000; Haralambieva et al, 2007).
In addition to directly lysing the tumor, the virus serves as an activator of 
the immune system (Prestwich et al, 2008; Boisgerault et al, 2010). Migrating 
immature cells of the immune system such as dendritic cells detect viral and 
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tumor-associated antigens produced by infected tumor cells and become 
activated (Moehler et al, 2005; Greiner et al, 2006). In turn, they recruit further 
immune cells (especially CD8+ T cells and NK cells), which attack the tumor 
cells, induce production of IFN and other signaling molecules (Errington et al, 
2008; Lech & Russell, 2010).
This fact was also confirmed by Diaz et al, when tumor bearing mice, 
lacking either CD8+ T cells or NK cells, were treated with oncolytic vesicular 
stomatitis virus (VSV). Both led to decreased oncolytic efficacy (Diaz et al, 
2007), compared to fully immune competent mice. Activation of the adaptive 
immune system therefore contributes an important part to the oncolytic 
virotherapy. 
1.3.4. Enhancing oncolytic effects
As already explained, a monotherapy with oncolytic viruses is insufficient 
and has to be enhanced (Liu et al, 2007). For this purpose, there are several 
approaches:
Combination with drugs is one possibility. With regard to virus clearance 
by the immune system, immunosuppressive drugs are being investigated. One 
of them is cyclophosphamide (CPA), a DNA-alkylating and immunosuppressive 
drug (Cattaneo et al, 2008). It has been shown that the combination with onco-
lytic viruses is synergistic. This is thought to be due to the fact that CPA 
reduces the concentration of antibodies (especially IgG), eliminates and inhibits 
proliferation of B- and T-lymphocytes and represses cellular innate antiviral 
immunity (Ikeda et al, 1999; Fulci et al, 2006; Qiao et al, 2008; Kottke et al, 
2009; Lun et al, 2009).
With respect to mechanic barriers hindering the delivery of drugs and also onco-
lytic viruses to the tumor site, there are approaches to increase vascular 
permeability and lower interstitial pressure within the tumor (Jain & 
Stylianopoulos, 2010). Administration of VEGF-repressor derivatives were 
shown to increase vascular permeability and hence reovirus infection of tumor 
11
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endothelium (Kottke et al, 2010). This could also be demonstrated by applying 
IL-2 in a mouse model of lung metastases, treated with VSV virotherapeutics 
(Kottke et al, 2008).
A combination of virotherapy with histone deacetylase inhibitors (HDACi) to 
decrease response of tumor cells to IFN and therefore increase susceptibility to 
viral infection also showed promising results (Nguyen et al, 2008).
Targeting is a concept that aims to direct viruses even more precisely to 
cancerous tissues. Due to either expression of different or overexpression of 
common proteins, tumor cells can be addressed more specifically. Using this 
basic principle, viruses can be modified to target such differentially expressed 
proteins. For example, Jing et al modified MeV's H-protein to bind to urokinase-
type plasminogen activator receptor (uPAR), which is frequently overexpressed 
in breast cancer, and could show a prolonged survival in a xenograft breast 
cancer model when treating with a targeted virus (Jing et al, 2009).
Another concept is to arm viruses by genetic manipulation (also called 
"arming"). Prodrug convertases, for example, can be transferred to the virus, 
which in turn brings the enzymes into the selectively infected tumor cells. The 
general idea is that these enzymes locally convert non-toxic to highly toxic 
substances (Knox & Connors, 1997; Cattaneo et al, 2008). 
Figure 1.4. Chemical structure of 5-Fluorocytosine (5-FC) (left) and 5-Fluorouracil (5-FU) 
(right). Taken from (Vermes et al, 2000).
12
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One system, which also has been used in this thesis, works with a fusion 
protein consisting of the enzymes cytosine deaminase (CD) and uracil phospho-
ribosyltransferase (UPRT), both derived from certain bacteria (E. coli) or fungi 
(Saccharomyces cerevisiae). CD catalyzes deamination of cytosine to uracil or 
5-fluorocytosine to 5-fluorouracil, respectively (Kilstrup et al, 1989). In contrast, 
neither do mammalian cells contain those enzymes, nor do they metabolize 
cytosine to uracil (Mullen et al, 1992). UPRT catalyzes the conversion of uracil 
to uracil monophosphate (UMP) and of 5-FU to 5-FUMP, which is an inter-
mediate step in the utilization of 5-FU (Kanai et al, 1998). This extra enzyme 
has been introduced because of the observation that some 5-FU resistant tumor
entities revealed mutations downstream in the pathway of 5-FU. With UPRT, 
this intermediate step and simultaneously this cause of 5-FU resistance can be 
evaded (Kanai et al, 1998; Erbs et al, 2000). Richard et al could also 
demonstrate that the intracellular prodrug conversion leads to far higher intra-
cellular concentrations of 5-FU than achievable by systemic administration. 
Therefore even slowly dividing tumor cells could be killed efficiently (Richard et 
al, 2007). The complete activation pathway of 5-FU is described in section 
1.2.2.
13
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Figure 1.5 5-FC activation and mechanisms of action. 
5-FC = 5-fluorocytosine, 5-FU = 5-fluorouracil, 5-FUMP = 5-fluorouridine 5‘ monophosphate, 5-
FUDP = 5-fluorouridine 5‘ diphosphate, 5-FUTP = 5-fluorouridine 5‘ triphosphate, CD = cytosine
deaminase, NK = nucleotide kinase, OPRT = orotate phosphoribosyltransferase, RNR = 
ribonucleotide reductase, TS = thymidylate synthase, UK = uridine kinase, UP = uridine 
phosphorylase, UPRT = uracil phosphoribosyltransferase. Figure based on (Cory et al, 1979; 
Piper & Fox, 1982; Thorn et al, 2011; Valeriote & Santelli, 1984).
These effects are highly toxic to mammalian cells but only occur in prodrug 
convertase-bearing cells. Those not being transformed escape the cytotoxicity 
(Mullen et al, 1992).
A chimeric protein, developed by Erbs et al, shows the activity of both enzymes 
and proved to be more efficient than the single enzymes (Erbs et al, 2000). 
Encoded by a replication-competent adenovirus (AdV) in combination with 5-
FC, treatment of breast, pancreas and colon cancer cells revealed to be 
efficient (Erbs et al, 2000; Chung-Faye et al, 2001). 
14
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A similar approach was undertaken with vaccinia virus to investigate the effect 
on HCC, liver metastases, breast, pancreas, colon and lung cancer and was 
also confirmed to show a potent enhancement of oncolysis (Erbs et al, 2008; 
Foloppe et al, 2008).
Additionally, 5-FU is highly diffusible and can kill non-infected surrounding cells 
(“bystander effect”). Huber et al could show that significant regressions in xeno-
graft models can be observed when as few as 2 % of all tumor cells express the
prodrug convertases (Huber et al, 1994). 
In conclusion oncolysis can be strongly enhanced by local prodrug toxification 
and diffusion of the toxified product to neighboring cells. This has already been 
confirmed in several in vitro and in vivo studies (Huber et al, 1994; Kanai et al, 
1998; Topf et al, 1998; Erbs et al, 2000).
A second example is a thymidine kinase-system. Thymidine kinase (TK) 
catalyzes phosphorylation of guanosine analogs like aciclovir (ACV) or 
ganciclovir (GCV) to the correspondent monophosphates. Cellular kinases 
further phosphorylate those resulting in metabolites, which then inhibit DNA 
synthesis (Moolten et al, 1990; Knox & Connors, 1997). When Boviatsis et al 
treated gliosarcoma-bearing rats with herpes simplex virus (HSV) with or 
without TK and added GCV, they could significantly prolong survival of those 
treated with TK and GCV (Boviatsis et al, 1994).
With the purpose to avoid early viral clearance and directing the virus to 
the tumor site, there are approaches to use carriers that naturally migrate to the 
tumor (so-called cell-mediated virus shielding approaches). This process is 
called “tumor cell homing” and can be used to deliver the virus to the tumor 
more efficiently, simultaneously protecting the virus from early clearance by the 
immune system. Therefore, suitable carriers (e.g. dendritic cells, leukocytes or 
even tumor cells) are infected ex vivo and administered before expression of 
viral antigens on their cell surface so that they can accumulate at the tumor site 
and locally produce high numbers of progenies (Harrington & Vile, 2006; Power 
& Bell, 2008; Ilett et al, 2011).
15
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Cytokine-induced killer cells, for example, can be obtained from the patient, 
infected with the oncolytic virus and then be reinfused. This principle was shown
to be synergistic when treating tumor-bearing mice (Thorne et al, 2006). 
Another example is the usage of lethally irradiated myeloma cells, which were 
able to carry and protect MeV in mice exhibiting anti-measles antibodies (Liu et 
al, 2010). Similar results could be obtained with activated T-cells as carriers of 
MeV (Ong et al, 2007). 
There are also approaches to lower the clearance by the 
reticuloendothelial system by simply increasing the dose of administered virus 
to saturate uptake or by shielding it with polymer coating (Fisher et al, 2001; 
Green et al, 2004; Manickan, 2006; Manickan et al, 2006). Depletion by 
monocytes could be decreased by simultaneous therapy with anticoagulants, 
clodronate, gadolinium and IgG (Ziegler et al, 2002; Shashkova et al, 2008). 
Additionally, monocyte receptors may be saturated by preincubation with 
polyinosinic acid (Haisma et al, 2008).
1.3.5. Clinical trials
The first clinical trials employing viruses to treat cancer began in the 
1950s. One of them was based on case reports about remission of Hodgkin's 
disease after onset of viral hepatitis. 21 patients were treated with sera and 
tissues extracts containing hepatitis virus and examined up to 12 months. 
However, it was concluded that "[…] the induction of viral hepatitis at the 
present time cannot be recommended as a therapeutic measure and should not
be used as a substitute for x-ray or nitrogen mustard therapy […]" (Hoster et al, 
1949). 
In contrast to such dissatisfying trials, results of current investigations are
much more promising.
So far, numerous viruses have been under investigation and administered to 
patients suffering from various tumor entities. Most importantly, latest trials 
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demonstrated acceptable, minimal or even no toxicity of any applied virus and 
safety could therefore be confirmed. According to Russell et al., AdV, 
Coxsackievirus, HSV, MeV, New castle disease virus, parvovirus, poliovirus, 
reovirus, Seneca valley virus, retrovirus, different vaccinia viruses and VSV are 
currently being investigated in phase I, II or III trials for the treatment of various 
solid tumors (Russell et al, 2012).
In the following, selected clinical trials are presented in short. 
Onyx-015 is a modified AdV that selectively replicates in and kills cells which 
harbour p53 mutations, which is often the case in tumor cells. It was the first 
engineered virus to be used in phase I and II clinical trials for the treatment of 
various tumors. In fact, therapy was very well tolerated in all cases. However, 
efficacy of single-agent therapy was disappointing, whereas response to 
chemotherapy could be enhanced in combination with Onyx-015 (Kirn, 2001; 
Liu et al, 2007). Another variant of AdV named H101 was approved for the 
treatment of head and neck cancer in combination with chemotherapy by 
Chinese authorities in 2005 (Garber, 2006). Tumor response could be 
significantly increased by combinational treatment with viruses and chemo-
therapy (Liu et al, 2007). 
In a phase II clinical trial, patients with unresectable metastatic melanoma were 
treated with oncolytic HSV type 1. The virus had been genetically engineered to
block antigen presentation, to express GM-CSF (vector depicted as T-Vec or 
Talimogene laherparepvec) in order to enhance the immune response and to 
selectively replicate in tumor cells. Final data clearly confirmed effectiveness 
with a 26 % objective response rate and an overall 1-year survival rate of 40 %. 
Therefore, a phase III study is already ongoing (Senzer et al, 2009) and 
approval of T-Vec by FDA and EMA as a first “Western“ virotherapeutic is to be 
awaited for 2015.
20 patients with primary or metastatic liver cancer were treated in a phase I trial 
with a modified vaccinia virus Ankara, bearing prodrug convertases CD and 
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UPRT (MVA-FCU1). The virus was injected intratumorally with doses of 107 to 4
x 108 into the tumor and subsequently the prodrug 5-FC was administered. 
Tumor response and the maximal tolerated dose should be investigated. 
However, study results have not yet been published (http://www.transgene.fr). 
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1.4. Armed oncolytic measles viruses
1.4.1. Introduction
In 1971, Bluming and Ziegler from the “Lymphoma Treatment Center of 
the Uganda Cancer Institute” published a case report on an eight year old boy 
suffering from a histologically diagnosed Burkitt’s lymphoma at the right orbita. 
Before any antineoplastic therapy could have been started, the patient had 
been naturally infected with wild-type MeV. Surprisingly, the orbital swelling dis-
appeared and the boy was in total remission for at least four months after 
infection (Bluming & Ziegler, 1971).
Fig. 1.6 Wildtype measles infection associated with remission of Burkitt’s lymphoma. The
first picture was taken on the 1st of December 1970 showing a swelling of the right orbita, 
histologically diagnosed as Burkitt’s lymphoma. Before the second picture has been taken on 
the 21st of December 1970, the boy had undergone an infection with wildtype MeV and had then
shown a detumescence. On the third picture, taken on the 6th of January 1971, there was 
neither a sign of the measles exanthema nor of the tumor. Taken from (Bluming & Ziegler, 
1971).
However, wildtype measles is still a dangerous disease and may cause 
severe complications (Schneider-Schaulies & ter Meulen, 2002). In contrast, the
vaccine strains are safe (Liu et al, 2007; Msaouel et al, 2012), but show similar 
anti-tumor activity though (Anderson et al, 2004).
This also applies to the MeV Edmonston vaccine strain, which already 
revealed to specifically infect and kill tumor cells, while hardly affecting normal 
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cells making the virus a tumor-selective agent (Anderson et al, 2004). 
Additionally, the vaccine strain indicated to be safe and to be efficiently 
oncolytic when treating first tumor patients in phase I / II clinical trials (Liu & 
Kirn, 2008; Galanis et al, 2010; Msaouel et al, 2012). Patients with 
subcutaneous T-cell lymphomas (Heinzerling et al, 2005) and patients with 
ovarian carcinoma (Galanis et al, 2010) were successfully treated. Therapy of 
further entities, such as glioblastoma multiforme and multiple myeloma, are 
under clinical investigation (Lech & Russell, 2010).
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1.4.2. Measles virus
Measles is a highly contagious viral disease that is caused by the 
homonymous measles virus. Before the successful vaccination was introduced, 
the virus had been responsible for approximately 2.6 million deaths per year 
(WHO, 2015). 
Fig 1.7 Schematic structure of measles virus. Directly underneath the lipid envelope (dark 
grey) with its embedded F- and H-proteins, the M-protein (yellow) surrounds the 
ribonucleoparticle, consisting of the P- and L-proteins (both blue) and the negative (-) stranded 
viral RNA (not shown), associated with the N-protein (black). Modified from (Springfeld, 2005).
The single virions are between 100 and 300 nm of size. From the outside
to the center of the virion, there is a phospholipid bilayer envelope, which is 
derived from budding off the host’s cell, containing hemagglutinin (H-protein) 
and the fusion (F-protein) protein. These integrated proteins are about 9 - 15 
nm long (Lamb and Kolakofsky, 2001). The H-protein, a type II glycoprotein, 
binds to cellular receptors SLAM, Nectin-4 and CD46 and it, together with the F-
protein, mediates membrane fusion for primary infection and formation of 
syncytia (Nussbaum et al, 1995). 
At the inside of the envelope, the matrix protein (M-protein) surrounds the
helical nucleocapsid, which consists of the nucleoprotein (N-protein), phospho-
protein (P-protein) and the large protein (L-protein). Together with the MeV 
nonsegmented, single stranded and negatively orientated RNA, the nucleo-
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capsid forms the ribonucleoparticle (RNP) (Griffin, 2001). Proteins V and C are 
non-structural and are not required for replication (Radecke & Billeter, 1996; 
Schneider et al, 1997).
Fig 1.8 Schematic diagram of measles virus' genomic structure. The genes are shown in 
their exact order, but the sizes are not drawn to scale. 
Measles mostly occur during winter and spring and are spread via droplet
infection. This highly contagious disease takes about 10 - 14 days of incubation,
until symptoms like cough, coryza, fever, a typical maculopapular rash and red 
spots at the buccal mucosa, called Koplik’s spots, emerge (Griffin, 2001). The 
severity of the disease and its symptoms is very much determined by the 
patient’s health status, age and immunocompetence (Schneider-Schaulies & ter
Meulen, 2002).
In 1954, T.C. Peebles (1921 - 2010) and J.F. Enders (1897 - 1985) were 
able to grow MeV on human kidney cell cultures from whole blood and throat 
washings of an infected 11 years old child called David Edmonston (Enders et 
al, 1957; Griffin, 2001; Msaouel et al, 2012). This isolated virus was then named
“Edmonston strain” or MeV-Edm. By transferring the virus to foreign hosts like 
chicken embryo cells, it slowly adapted to the new conditions and therefore 
became attenuated and able to be used as a live vaccine (Griffin, 2001; 
Msaouel et al, 2012), not giving any cause of concern about its safety 
(Schneider-Schaulies & ter Meulen, 2002; Liu et al, 2007). The strain being 
mostly used for vaccination all over the world obtained licence in 1965 (Griffin, 
2001). A reversal so that the virus retrieves its former pathogenic abilities, for 
example to spread among other individuals, has never been observed or 
reported so far (Msaouel et al, 2012). Moreover, the measles vaccine has been 
used for about one billion people during the last 40 years, confirming its 
harmlessness (Msaouel et al, 2012). Only patients with a severe immuno-
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deficiency (e.g. AIDS) may develop a serious infection and should therefore not 
be vaccinated (Kaplan et al, 1992; Lech & Russell, 2010). 
The Edmonston vaccine strain is also very suitable for genetical 
manipulation, as it can accept huge genetic insertions (> 6 kb) and maintain 
stability in vitro as well as in vivo.
1.4.3. Oncolytic characteristics of measles vaccine virus
Malignant cells have defects in their innate antiviral immunity, making 
them susceptible for viral infections (see section 1.3.3.). In return, MeV-Edm is 
attenuated in its ability to suppress the IFN induced antiviral state in healthy 
cells and is therefore easily repelled by untransformed cells. In contrast, tumor 
cells are just lacking these characteristics und are unable to establish an anti-
viral state, which makes them an ideal target for measles vaccine virus.
Another feature of measles vaccine virus is its receptor tropism. CD46 
serves as the main receptor for infection and it has been found that, compared 
to normal cells, most tumor cells overexpress CD46. This might be due to the 
protective effect of CD46 against mechanisms of complement-mediated lysis 
(Fishelson et al, 2003; Anderson et al, 2004), constituting a clear advantage for 
malignant over normal cells. 
This difference in CD46 receptor density makes cancer tissues a suitable target 
for MeV therapy, in particular for the Edmonston vaccine lineage with its distinct
receptor tropism. This way, cancer cells can be selectively infected and lysed, 
whereas non-malignant cells are relatively unaffected, showing only little and 
negligible signs of infection (Anderson et al, 2004).
Moreover, not only the primary infection rate is increased, but also viral spread 
via formation of syncytia is enhanced significantly. Neighboring tumor cells 
which are not infected primarily are then likely to be gathered into cytopathic 
syncytia, which is also due to overexpression of CD46 (Anderson et al, 2004).
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Certainly, measles vaccine virus has a clear disadvantage. In contrast to 
other oncolytic viruses, almost everyone has already had contact to measles 
(mostly the vaccine) and is therefore likely to have preexisting antibodies. Even 
low titers would intercept systemically applied virus thus lowering or even 
completely eliminating the therapeutic agent.
1.4.4. Arming of oncolytic measles vaccine virus
To enhance the oncolytic activity of measles vaccine virus, the virus can 
be modified genetically. Importantly, the genetic modification of the virus doesn’t
impair its oncolytic activity (Msaouel et al, 2012).
One approach is to modify measles vaccine virus with a gene encoding 
the soluble marker protein CEA. Measuring its levels can therefore monitor real-
time viral gene expression kinetics. 
Another possibility to trace local viral spread and replication is to deliver 
the thyroidal sodium iodide symporter (NIS), a membrane ion channel that 
transports radioisotopes into cells. Isotopes can therefore be used for detection 
and also for therapeutical local radiation therapy approaches (Msaouel et al, 
2009).
 
In this thesis, an armed MeV virotherapeutic vector encoding a 
combinational fusion protein of CD and UPRT, called super cytosine deaminase
(SCD), was used. (The mechanism of action has already been explained in 
section 1.3.4.) The gene encoding the SCD is expressed from the leader 
position at the 3' ending within the measles genome.
Fig. 1.9 Genome of engineered measles vaccine virus MeV-SCD. The gene encoding for the
fusion protein super cytosine deaminase (SCD), which has a combined and enhanced activity of
cytosine deaminase and uracil phosphoribosyltransferase, is expressed from the leader position
at the 3' ending.
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1.4.5. Clinical trials with oncolytic measles virus
In the first phase I clinical trial with measles vaccine virus, 5 patients with
cutaneous T-cell lymphoma (CTCL) received intratumoral injections of an 
unmodified measles Edmonston-Zagreb vaccine strain after pretreatment with 
IFN-γ. CTCL are known to have defects in their IFN signaling and were 
therefore considered as an ideal target for the oncolytic virotherapy. 
Pretreatment with IFN-γ should avoid uncontrolled virus spread.
In addition to demonstrating tolerance and safety, four tumors showed a partial 
response whereas one lesion even resulted in total remission (Heinzerling et al, 
2005).
In another phase I clinical trial, for the first time an engineered measles 
vaccine virus was administered. 21 patients with refractory and peritoneally 
metastasized ovarian cancer were treated with MeV expressing the soluble 
marker protein CEA (MeV-CEA). The virus was injected intraperitoneally and 
viral gene expression could be monitored by measuring CEA levels. Safety was 
confirmed, expression of the CEA marker gene could be detected in some 
patients and expected median survival has been doubled (Galanis et al, 2010). 
MeV-CEA is currently also applied in patients with recurrent glioblastoma
multiforme. The virus is either administered directly after surgical resection of 
the tumor (Group A) or 5 days before surgery with an implanted catheter (Group
B). Tumors of group B are then resected and virus is readministered. The study 
is still running and has not yet been completed 
(http://www.clinicaltrials.gov/ct2/show/NCT00390299).
Patients with refractory or recurrent multiple myeloma are currently 
treated with MeV-NIS (encoding for a thyroidal sodium iodide symporter) with or
without addition of CPA in a clinical phase I trial. Imaging by 123I administration 
is performed to observe biodistribution and kinetics of viral spread 
(http://www.clinicaltrials.gov/ct2/show/NCT00450814). In 2014, Russell and 
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colleagues reported on a durable complete remission of a heavily pretreated 
multiple myeloma patient after a single-shot intravenous infusion of MeV-NIS 
(Russell et al, 2014). This was the first documented in-human case to prove the 
so called “oncolytic paradigm” (Russell et al, 2012) that systemically 
administered oncolytic viruses selectively infect disseminated sites of cancer 
with subsequent tumor-destruction and further detectable replication as self-
amplifying biologicals. This hallmark case documents the possibility to cure 
cancer patients with a single infusion of MeV-based, but circumstances for this 
specific patient obviously were rather exceptional than being the rule for other 
cancer patients. For example, multiple myeloma showed to be a tumor entity 
being very well qualified for oncolytic measles vaccine therapy due to its distinct
tumor biology and the patient described in the study has been seronegative for 
anti-measles antibodies at the onset of virotherapeutic treatment, thereby likely 
avoiding any rapid neutralization of infused measles vectors.
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1.5. Objective
Oncolytic virotherapy with measles vaccine virus has already been 
demonstrated to be safe. However, early clinical results pointed out the 
necessity for an enhancement of oncolytic effectiveness of MeV-based 
virotherapeutics.
In our work, we are developing an armed measles vaccine virus MeV-
SCD encoding a suicide fusion gene of yeast cytosine deaminase and uracil 
phosphoribosyltransferase, converting the non-toxic prodrug 5-FC to the 
chemotherapeutic drug 5-FU (European patent EP2605783 granted for MeV-
SCD on 2015-03-25).
To preclinically investigate how an optimal prodrug-assisted therapeutic 
regimen could look like, we added 5-FC at different time points after infection 
with MeV-SCD and either let the prodrug remain in the tumor cell culture 
medium continuously for different time periods (“continuous” 5-FC application) 
or applied it only temporarily for defined shorter time periods (“pulsed” 5-FC 
application). We also varied the time point at which 5-FC was added after 
infection with MeV-SCD.
To be able to compare direct treatment with 5-FU to our SCD-armed viro-
therapeutic approach (based on enzymatic conversion of 5-FC to 5-FU), all 
tumor cell lines were also tested for their “base-line” sensitivity to 5-FU.
In addition, we examined the influence of prodrug addition on viral (MeV-
SCD) replication. Treatment with cytostatic compounds such as 5-FU could not 
only kill tumor cells, but possibly influence replication of virotherapeutic vectors 
as well. In order to find out whether 5-FC prodrug conversion compounds might 
exert an impact on virotherapeutic replication, viral growth curves were 
performed.
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2. Material and Methods 
2.1. Material
If not described in any other way, all mentioned materials have been 
used in the highest achievable purity. These were either directly obtained in a 
sterile state from the cited companies or treated by autoclaving at 2 bar 
pressure and 121 °C for 20 minutes.
Only water that has been deionized and filtered (H2Odd) was used for 
experiments, unless declared differently.
2.1.1. Consumables
Cell scrapers Corning Inc.
Cell strainer 40 µm BD Falcon
Combitips 2.5 ml, 12.5 ml Eppendorf
Conical-bottom tube 15 ml Greiner Bio One
Conical-bottom tube 50 ml BD Falcon
Cryotubes 1 ml Corning Inc.
Pasteur pipettes, 230 mm long size WU Mainz
Pipettes 5 ml, 10 ml, 25 ml, 50 ml Corning Inc.
Pipette tips 100 µl, 200 µl, 1000 µl, 1250 µl Biozym / Peqlab
Reaction tubes 1.5 ml, 2.0 ml Eppendorf
Reaction tubes 1.5 ml, 2.0 ml (amber)  Eppendorf
Tissue culture flask 75 cm², 150 cm² Greiner Bio One
Tissue culture plate 6 well Corning Inc.
Tissue culture plate 24 well TPP
Tissue culture plate 96 well TPP / Corning Inc.
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2.1.2. Chemicals
5-Fluorocytosine Roche
5-Fluorouracil Pharmaceutical Department, 
Universitätsklinikum Tübingen
Acetic Acid Merck
Descosept Dr. Schuhmacher GmbH
DMSO AppliChem 
Isopropanol (70%) SAV Liquid Production
Paraformaldehyde (PFA), 4.0 % Otto Fischar GmbH
Secusept ECOLAB
Sulforhodamine B Sigma Aldrich
Trichloroacetic acid Carl Roth
TRIS Carl Roth
Trypan blue SIGMA
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2.1.3. Antibodies
Alexa Fluor® 546 Invitrogen
Goat Anti Mouse IgG (H+L), A11003
MeV N-Protein NP clone 120 ECACC
Mouse IgG2
2.1.4. Media, Sera and Buffer
DMEM BIOCHROME
EDTA Trypsin Lonza
Fetal Calf Serum Gibco
Opti-MEM Gibco / Life Technologies
PBS (cell culture use) PAA
RPMI 1640 PAA
Tween-20 Carl Roth
self-made solutions:
PBS (non cell culture use) NaCl 137 mM (8 g)
KCl 2.7 mM (0.2 g)
Na2HPO4 10 mM (1.44 g)
KH2PO4 1.8 mM (0.24 g)
H2Odd filled up to 1 l
SRB dye (0.4 % in 1 % acetic acid) SRB 4 g
Acetic acid 10 ml
H2Odd filled up to 1 l
10 x TBS (Tris-buffered saline) NaCl 1.5 M (438.3 g)
TRIS 0.5 M (302.85 g)
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pH    7.4, adjusted with HCl
H2Odd filled up to 5 l
TBS-Tween (0.02 %) Tween-20 5 ml of 20 %
10 x TBS 500 ml
H2Odd filled up to 5 l
TCA solution (10 %) TCA 100 g
H2Odd filled up to 1 l
TRIS base TRIS 10 mM (1.21 g)
H2Odd filled up to 1 l
pH 10.5
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2.1.5. Cell lines
COLO205 colorectal adenocarcinoma (Duke’s Type D) with 
ascites metastases and CEA production, taken from 
a 70 year-old male of Caucasian origin, who has 
been treated with 5-FU 4-6 weeks prior to cell 
rescue. Purchased from ATCC (NCI).
HCC2998 colorectal adenocarcinoma
HCT116 colorectal adenocarcinoma
HCT15 colorectal adenocarcinoma
Hep3B hepatocellular carcinoma, containing hepatitis B 
virus genome and producing hepatitis B surface 
antigen 
(HBsAg) therefore requiring laboratory safety level 2.
Cells taken from an 8 year-old, coloured boy 
purchased from ATCC (NCI).
HT29 colorectal adenocarcinoma, grade 3 taken from a 44 
year-old woman
HuCCT-1 human bile duct carcinoma, producing CA19-9 and 
with ascites metastases taken from a 56 year-old 
male
purchased from Riken Biosource Center
KM12 colorectal adenocarcinoma
SW620 colorectal adenocarcinoma, with metastases, taken
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from a 51 year-old male
Vero african green monkey kidney cells
purchased from the German Collection of 
Microorganisms and Cell Cultures (DSMZ,
Braunschweig, Germany)
2.1.6. Virus
MeV-SCD Wolfgang Neubert
2.1.7. Laboratory Equipment
Autoclave 3850 EL Systec
Centrifuge Eppendorf, Heraeus
Fluorescence microscope Olympus
Haemocytometer Hecht Assistant
lncubator Heraeus / Integra / Memmert
Laminar Flow Work Bench Heraeus
Light microscope Olympus
Multichannel pipette Eppendorf
Handystep Brand
Photometer Genios Plus Tecan
Pipette Boy Integra
Pipettes BioHit / Eppendorf 
Refrigerator (-18 °C, -80 °C, -120 °C) Liebherr
Rotational Vacuum Concentrator Christ
Vortexer Janke + Kunkel IKA Labortechnik
Water bath 3042 (37 °C) Köttermann
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2.2. Methods
2.2.1. Safety
The laboratory, in which all experiments have been performed, complies 
with Biosafety Level 2 of the Directive 2000/54/EC – biological agents at work 
from the European Parliament from the year 2000. Therefore, working with 
potentially infectious or hazardous biological particles was performed under a 
laminar flow hood (HERAsafe®). Afterwards, all materials were thoroughly 
desinfected, irradiated with UV-light for at least 15 minutes and additionally 
autoclaved. 
2.2.2. Software
Calculations were done with Microsoft Excel 2003 and afterwards 
depicted and statistically analyzed with GraphPad Prism4 and GraphPad 
Prism6 (GraphPad Software). 
2.2.3. Cell culture
Cells were cultivated in either DMEM or RPMI medium, supplemented 
with 5% or 10 % fetal calf serum (FCS) and kept in 75 cm2 tissue culture flasks 
with vented caps. Flasks were stored in incubators at 37 °C in a humid 
atmosphere, containing 5 % CO2. Treatment was done under sterile conditions 
in a HERAsafe® workbench.
2.2.3.1. General cell culture 
To harvest or split cells, they were first washed with warmed (37 °C) PBS
and then incubated with EDTA-Trypsin, until the cells detached from the bottom.
Trypsin was inactivated with FCS-supplemented medium. Single cell 
suspensions were generated by properly resuspending with a pipette. If 
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necessary, the suspension was additionally filtered through a 40 µm cell 
strainer. 
After harvesting the required amount of cells, fresh medium was added 
and the flask was again stored in the incubator.
2.2.3.2. Counting cells with a haemocytometer
In order to determine the concentration of cells in a suspension, a 
haemocytometric technique was used. The improved Neubauer counting 
chamber has engraved squares of different sizes. A large square, consisting of 
16 smaller squares, measures 1 mm2. 
To use the Neubauer haemocytometer, the covering glass was put onto 
the moistened haemocytometer and rubbed carefully along the two elevated 
glass edges, until so called "Newton rings" appeared. These colours of 
interference indicate that between the glass edges and the counting chamber, 
there’s only enough space for the light to pass through, which means that this 
distance can be neglected, whereas the gap between the coverglass and the 
counting chamber is exactly 0.1 mm big. 
When the coverglass was properly fixed, a small amount (approximately 
10 µl) was pipetted closely beside the coverglass. The capillary force then 
soaked the liquid just into the gap. 
Using a microscope with a 10x objective, it was possible to count the 
cells in each large square. The number of cells counted in one square is diluted 
in a defined volume of 0.1 µl, which results from the size of the square (1 mm2) 
and the height of the gap (0.1 mm). The calculated volume equates to exactly 
0.1 mm3, which is 0.1 µl. 
Additionally, a colouring chemical could be added to exclude dead cells 
from the counting. Trypan blue (also Benzamineblue or 3,3′-Dimethyl-4,4′-bis(5-
amino-4-hydroxy- 2,7-disulfonaphtyl-3-azo)-[1,1′-biphenyl]) is a diazo dye. 
Trypan blue allows distinguishing between dead and living cells, as the intact 
membrane of living cells doesn’t let the chemical pass whereas it can enter the 
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dead cells and colour their protein. Under the microscope, dead cells appear 
dark blue. 
Using this technique, the factor of dilution was considered when 
counting.
2.2.3. Cryoconservation and thawing
To store cells for a longer time they were cryoconserved at
-145 °C. Therefore, the harvested and medium-suspended cells were 
sedimented by centrifuging at 1200 rpm for 2 minutes. The supernatant was 
removed and the remaining cell pellet was resuspended in cryomedium (90% 
RPMI (+20%FCS), 10% dimethyl sulfoxide (DMSO)). After apportioning to 
several cryotubes of 1 ml each, everything was packed into a styrofoam box or 
an isopropanol bath to assure a slow cool-down to -80 °C. The following day, 
the frozen cryotubes were transferred to a -145 °C freezing cabinet. 
When thawing single cryotubes to recultivate the frozen cells, they were 
thawed in a water bath. Cells were added to 9 ml prewarmed medium and 
centrifuged at 1200 rpm for 2 minutes to remove toxic DMSO. After 
resuspending the cell pellet in fresh and warmed medium, the cells were 
transferred into a new tissue culture flask.
2.2.4. Virological methods
2.2.4.1. Infection of cells and application of 5-FC 
Cells were seeded in 24 well plates at a density of 3 x 104 cells per well 
and allowed to adhere overnight. On the infection day, the virus was thawed 
carefully, vortexed and, depending on the needed MOI (multiplicity of infection), 
diluted in room-tempered Opti-MEM. 
The medium was then removed and cells were washed with warmed 
PBS once. After that, the virus was added to the cells and incubated for 3 hours
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at 37 °C. Every 20 minutes, the plates were carefully swayed in order to ensure 
a sufficient contact of virus to cells.
Three hours post infection (hpi), the inoculum was removed and replaced
by warmed medium. If intended, the prodrug 5-FC was either added to the 
medium before pipetting into each well or directly pipetted into the wells. 
Importantly, the factor of dilution was considered. 
If the prodrug should be added only for a certain period of time (e.g. 6 
hour pulse) and taken off afterwards, the medium from the respective well was 
transferred to an empty plate, which was also stored and incubated under same
conditions for the time of prodrug application. When the time had passed, the 
prodrug containing medium was removed and replaced by the medium which 
had been set aside. 
The advantage of this technique compared to replacing the prodrug-
containing medium by fresh medium was clearly to observe as the medium was 
preserved in each state of consumption and hence not induced proliferation as 
much as fresh medium does. In addition, no virus was lost.
As 5-FC is light sensitive, the light was switched off while working with 
the substance. 
2.2.4.2. Creating a virus growth curve
In order to determine the viral growth kinetics in an experimental 
approach, samples were taken at certain time points post infection.
Therefore, cells were seeded in 6 well plates at a density of 1 x 105 cells per 
well in 2 ml RPMI + 10 % FCS. On the following day they were infected at an 
MOI of 0.03 or 0.3 in 1 ml Opti-MEM. 3 hpi, the inoculum was removed and 
cells were washed three times with warmed PBS to remove all unbound virus. 
Then 1.5 ml RPMI + 5 % FCS was added. Notably, the medium contained only 
5 % FCS, as cellular proliferation shouldn’t be induced too much.
At different time points post infection, samples were taken. 
For this purpose, first the supernatant of a suitable well was transferred to a 2 
ml reaction tube, then 1 ml room-tempered Opti-MEM was added to gather cells
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and nascent virus when scraping the cells off the well’s ground. After 
resuspending properly, the solution was transferred into another 2 ml reaction 
tube. Samples were then frozen at -80 °C without adding any anti-freezing 
agent to make the cells burst open and release the intracellular virus.
2.2.4.3. Titration of virus
One day prior to titration, Vero cells were plated in a 96 well plate at a
density of 1 x 104 cells per well in 200 µl DMEM supplemented with 5 % FCS. If 
the Vero cells looked healthy and properly attached to the well's ground titration
of virus was performed. For this purpose, the samples obtained as described 
above (2.2.7.2.) were thawed in a waterbath at 37 °C, vortexed for at least 15 
seconds and then centrifuged for 2 minutes at 3000 rpm. The supernatant was 
then used as the virus-containing sample that should be examined.
To identify an unknown concentration of virus, basically a serial of 1:10 
dilution of the undefined virus sample is used to infect a for the virus optimal 
system (Vero cells in case of measles). To prepare the dilution serial, 300 µl 
supernatant of a centrifuged reaction tube was pipetted to the first well of each 
8 well row of an empty 96 well plate. The following 7 wells were filled with 270 µl
DMEM + 5 % FCS. By transferring 30 µl from one well to the following, 
suspending properly and changing pipette tips after each step, a 1:10 serial 
dilution of each aliquot with 8 different concentrations was obtained. 
With a multichannel pipette, each row of dilution was transferred to four 
rows of a 96-well Vero cell plate with 50 µl for each well. That way, each aliquot 
with 8 different dilutions was given to prepared Vero cells, so that, if containing 
virus at its state of dilution, it was able to infect the Vero cells.
After 96 hours of incubation cells were first washed with 200 µl PBS once
and then fixed with 50 µl 4 % paraformaldehyde, dissolved in PBS and 
incubated for ten minutes at room temperature. Following fixation, the plate was
again washed with 200 µl PBS twice. 
The next step was to block with 100 µl 1 % FCS in TBS-Tween to avoid 
unspecific binding. This was followed by incubation with an anti-MeV-N protein 
38
Material and Methods
antibody, diluted 1:1000 in TBS-Tween for 30 minutes. After 3 steps of washing 
with TBS-Tween, the secondary antibody goat anti-mouse, also diluted 1:1000 
in TBS-Tween, was added. The 30 minutes of incubation with the secondary 
antibody were performed in the dark to preserve the fluorescent potential and 
were then followed by another 3 steps of washing with TBS-Tween. At last, the 
wells were filled up with 100 µl PBS each to avoid drying out. 
Using a fluorescence microscope, replication competent MeV infection 
could be detected and all measles-positive wells identified. As soon as there 
were more than single cells showing fluorescence, the well was determined as 
“positive”, whereas isolated single fluorescent signals were seen as replication 
incompetent measles and therefore excluded. The extent of viral spread and 
cytopathic effect was not considered. 
With these information, the titer could be expressed with the “tissue 
culture infective dose 50”, describing the amount of virus causing 50 % positive 
inoculations of all (Condit, 2001). To make the unit more descriptive, it was 
transformed to pfu / ml. The titer was calculated by the Spearman-Kärber 
Method (Spearman, 1908; Kärber, 1931). 
2.2.5. Microscopy
To control a certain treatment or culturing of cells, these were 
continuously examined under the microscope to guarantee sterile and proper 
conditions. Therefore, the phase contrast microscope CK40 from Olympus was 
used.
If any fluorescence had to be detected, the fluorescence microscope 
IX50 from Olympus has been used.
2.2.6. Sulforhodamine B Assay
The sulforhodamine B assay (SRB-assay) is a technique to quantify the 
amount of cells by staining cellular protein unspecifically. Therefore, it is 
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possible to monitor the cytotoxicity of a given drug or intervention when 
comparing mock-treated with drug or virus treated cells.
SRB, an aminoxanthene dye with two sulfonic groups, attaches to basic 
amino acids of cellular proteins under mild acidic conditions.
When dissolved, the coloured cells can be measured photometrically. The 
colorimetric extinction is linear to the amount of cellular protein (Skehan, 1990).
In order to prepare cells for analysis via SRB-Assay, the medium was 
removed, the cells were washed with cold PBS (4 °C) and covered with cold 
TCA. After incubating for at least 30 minutes at 4 °C, the fixed cells were rinsed 
with tap water four times and dried overnight at 40 °C.
Then cells were stained with SRB solution for 10 minutes and subsequently 
washed with 1 % acetic acid until the washout became colourless. The plates 
were again dried and thereafter dissolved in 1000 µl Tris base. 
From each well, 80 µl were transferred in duplicates to a 96-well plate. The 
photometrical extinction was then measured in a microtiter plate reader (Tecan 
Genios Plus) at a wavelength of 564 nm. Treated cells were compared to the 
corresponding mock-treated and the relation was given in percent. 
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3. Results 
In order to establish an optimized application scheme for the prodrug 5-
FC to treat tumor cells of gastrointestinal origin, which have been infected with 
an armed oncolytic measles vaccine virus, the following data were collected.
First of all, it was necessary to determine suitable dosages of infections, 
i.e. multiplicities of infection (MOIs), and appropriate prodrug concentrations for 
each and every tumor cell line. The two lowest MOIs that were just not able to 
kill the cells in the course of sole infections (threshold MOIs) were chosen. 
Additionally, also a threshold concentration of 5-FC moderately enhancing the 
oncolytic effect was identified. With these information, shown in section 3.1., it 
was possible to compare different approaches for prodrug application. Basically,
a continuous versus a pulsed addition was examined, which is illustrated in 
sections 3.2. and 3.3. (Yurttas et al, 2014).
Secondly, the sensitivity to 5-FU was surveyed, so that differences in 
response to chemotherapy with 5-FU alone and virotherapy with prodrug 
conversion could be identified, shown in part 3.4. (Yurttas et al, 2014).
Thirdly, the effect of prodrug conversion not only on the tumor cells, but 
also on virus replication was examined. For this purpose, virus growth curves 
(section 3.5.) were performed (Yurttas et al, 2014). 
3.1. Identification of threshold MOIs
To find out which two MOIs of MeV-SCD were suitable for further 
experiments with each tumor cell line, each of them was infected with 
ascending virus concentrations (MOIs 0.01, 0.1, 1, and 10). At 3 hours post 
infection (hpi) medium alone or medium supplemented with 5-FC (0.1 or 1 mM) 
was added.
At 144 hpi, all tumor cells were fixed for analysis via SRB viability assay.
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Figure 3.1. Application scheme for the determination of suitable (threshold) MOIs for 
each tumor cell line. Tumor cells were plated and infected or mock treated the following day. 
Additional medium with or without 0.1 mM 5-FC was added at 3 hours post infection (hpi) and 
remained there until the end of the experiment at 144 hpi, followed by quantification of remnant 
tumor cell masses by SRB viability assay. mM = millimolar, 5-FC = 5-fluorocytosine, hbi = hours
before infection, hpi = hours post infection.
As a result, the oncolytic effect of the viral infections was found to be 
increased when using higher MOIs. Most of the tumor cell lines (except for 
SW620 and Hep3B) showed little response to the lowest MOI of 0.01. Whereas 
SW620 and Hep3B cells were almost completely eradicated with increasing 
MOIs, the other tumor cell lines were less sensitive. 
However, addition of the prodrug 5-FC significantly enhanced oncolysis. 
At a concentration of 1 mM 5-FC the tumor cell mass was reduced already too 
much, so that even at the lowest MOIs tumor cells were hardly found left over at
the end of the experiment. Therefore 0.1 mM 5-FC was used for all further tests.
By purpose, two MOIs to be used in further experiments were defined for
each tumor cell line. For tumor cell lines HCT116, HT29, SW620, HCC2998, 
Hep3B, HuCCT-1, and COLO205, infection with MOI 0.01 alone showed little 
response but was already effectively killing most tumor cells when adding 0.1 
mM 5-FC. For this reason, although not tested in this setting, MOI 0.001 was 
chosen as the second MOI to be used in the following investigations.
For KM12, MOIs 0.01 and 0.1 were determined and for HCT15, being the
least responsive tumor cell line, MOIs 0.1 and 1 were found to be most 
adequate. All given MOIs and 5-FC concentration are listed in table 3.1.
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Figure 3.2. Determination of suitable MOIs for each tumor cell line. Tumor cells were mock 
treated or infected with MeV-SCD at MOI 0.01, 0.1, 1, and 10. Additional medium with or 
without 0.1 mM 5-FC was added at 3 hpi and remained there until the end of the experiment at 
144 hpi; then, all remaining tumor cells were fixed with TCA. Remnant tumor cell mass was 
quantified via SRB assay. Values: mean of three independent experiments performed in 
triplicates. Error bars: SEM.
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Table 3.1. Results of the pre-test with two suitable MOIs and 5-FC concentrations for 
each tumor cell line. MOI = multiplicity of infection, 5-FC = 5-fluorocytosine, mM = millimolar.
3.2. Continuous application of 5-FC
With the findings from the pre-testing depicted in section 3.1., different 
approaches for the prodrug application could be investigated next. Each tumor 
cell line was infected with the two afore ascertained MOIs and 0.1 mM 5-FC 
was added either at 3 hpi, 24 hpi, 48 hpi or 72 hpi. At 144 hpi, all cells were 
fixed with TCA for analysis. This way, the time point post infection at which 
prodrug application shows the most effective oncolysis should be identified 
(Yurttas et al, 2014).
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Figure 3.3. Application scheme for the continuous prodrug treatment of MeV-SCD 
infected tumor cells. Tumor cells were plated and infected or mock treated the following day. 
Additional medium with or without 0.1 mM 5-FC was added at 3 hpi, 24 hpi, 48 hpi or 72 hpi, 
respectively, and remained there until the end of the experiment at 144 hpi, followed by 
quantification of remnant tumor cell masses.
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Figure 3.4. Effect of continuous prodrug application. Cells were mock treated or infected 
with MeV-SCD at MOI 0.01 or 1, respectively. Additional medium with or without 0.1 mM 5-FC 
was added at 3 hpi, 24 hpi, 48 hpi or 72 hpi (from left to right) and remained there until the end 
of the experiment at 144 hpi; then, all remaining cells were fixed with TCA. Remnant tumor cell 
mass was quantified via SRB assay. Values: mean of three independent experiments 
performed in triplicates. Error bars: SEM. (Yurttas et al, 2014)
 
Each cell line was treated in 6 different groups. The first group, 
represented by the first 4 columns in each graph, was mock treated and 
received extra medium without 5-FC at 3 hpi, 24 hpi, 48 hpi or at 72 hpi, 
respectively. The second and third group were infected with the two MOIs, 
which had been defined for each cell line. The fourth to sixth group were treated
in the same way as the first to third, but received medium containing 0.1 mM 5-
FC at 3 hpi, 24 hpi, 48 hpi, or 72 hpi.
The mock treated first group was set to 100 % cell mass. Groups two 
and three, which were infected with the two corresponding MOIs only, differed 
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only slightly from the mock treated, which complies with the defined conditions 
from the pre-test. 
Group four was given extra medium with 0.1 mM 5-FC at the mentioned 
time points only, demonstrating no cytotoxicity. Quite the contrary, most cell 
lines proliferated marginally.
In contrast, virus and prodrug treated groups five and six clearly 
demonstrated enhanced oncolysis, compared to the corresponding groups two 
and three, which were infected without addition of 5-FC. In fact, cell lines 
HCT116, HT29, COLO205, SW620 and HuCCT-1 hardly responded to infection
with corresponding lower MOI and prodrug addition at all, but HCT15, 
HCC2998, Hep3B and KM12 were already killed efficiently.
Infection with the higher MOI, combined with prodrug application, 
demonstrated oncolytic activity in all cell lines. Clearly, the time point post 
infection when 5-FC was added made a difference. The earlier and longer 5-FC 
was appended, the less the remaining cell mass 144 hpi, compared to mock 
treated. Whereas treatment of SW620 exhibited to be the least time-dependent,
all other cell lines confirmed the observation (Yurttas et al, 2014).
However, it was not possible to determine, whether the enhanced effect 
was due to the duration of incubation with 5-FC only, the time point of prodrug 
addition only or because of both of them. As all cells were fixed at 144 hpi, 5-FC
was not only added at different points of time, but also for variable time periods. 
As the mock treated wells were already overgrown at 144 hpi and the medium 
therefore almost used up, it was impossible to prolong incubation periods 
beyond 144 hpi. To circumvent this problem, a new approach was chosen.
As treatment with the corresponding higher MOI and prodrug addition 3 
hpi and 24 hpi showed best results, only these conditions were further 
investigated. Also, only cell lines HCT116 and HCT15 were used for the 
following experiments. The cells were infected and 3 hpi or 24 hpi, 5-FC was 
added. Starting 24 hours after application of the prodrug, every 24 hours until 
144 hpi one sample was fixed and analysed by SRB-Assay. This way, a kinetic 
of the remaining cell mass could be created (Yurttas et al, 2014). 
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Figure 3.5. Application scheme for the time-dependent effect of continuous prodrug 
treatment at 3 hpi. Tumor cells were plated and infected or mock treated the following day. 
Additional medium with or without 0.1 mM 5-FC was added at 3 hpi and remained until the end 
of the experiment at 24, 48, 72, 96, 120 and 144 hpi. Remnant tumor cell masses were 
quantified by SRB assay.
Figure 3.6. Application scheme for the time-dependent effect of continuous prodrug 
treatment at 24 hpi. Tumor cells were plated and infected or mock treated the following day. 
Additional medium with or without 0.1 mM 5-FC was added at 24 hpi and remained until the end
of the experiment at 48, 72, 96, 120 and 144 hpi. Remnant cell masses were quantified by SRB 
assay.
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Figure 3.7. Time-dependent effect of continuous prodrug application. Cells were mock 
treated or infected with MeV-SCD at MOI 0.01 or 1, respectively. Additional medium with or 
without 0.1 mM 5-FC was added either at 3 hpi (panels to the left) or at 24 hpi (panels to the 
right) and remained on target cells continuously. Incubations were stopped at 24 hpi (panels to 
the left: only when 5-FC was added already 3 hpi), or at 48, 72 , 96, 120 and 144 hpi (all 
panels); remaining cells were fixed with TCA and remnant cell masses were determined by SRB
assay. Values: mean of three independent experiments performed in triplicates. Error bars: 
SEM. (Yurttas et al, 2014)
    
The columns of each group show the remaining cell mass in percent of 
mock treated developing along the time up to 144 hpi. At every time point, the 
control was set to 100 %. Virus infection alone caused a constantly decreasing 
cell mass in HCT116, whereas HCT15 reached a minimum approximately at 72 
hpi to 96 hpi, hereon showing increasing cell mass.
Addition of 5-FC at 3 hpi or 24 hpi to mock infected control cells resulted 
in slightly increased cell mass, as already noticed.
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Infected and prodrug treated cells again revealed enhanced oncolysis. 
Whereas cell mass of HCT116 was constantly reduced to roughly 75 % until 
144 hpi, the cellular mass of HCT15 mainly decreased shortly after prodrug 
addition. Besides, application of 5-FC at 24 hpi led to a comparable effect after 
144 hpi as seen when given 3 hpi. The incubation period for 5-FC added at 24 
hpi was indeed shorter; however, the relative reduction of cellular mass per 24 
hours until 144 hpi was larger, seen especially shortly after addition (Yurttas et 
al, 2014).
To contemplate time points of prodrug application in an isolated manner, 
data from cells, which were treated with 5-FC for an equal time period, but 
where treatment was started at different time points (3 hpi, 24 hpi, 48 hpi, or 72 
hpi) were compared (Yurttas et al, 2014).
Figure 3.8. Comparison of the oncolytic effectiveness of MeV-SCD infected tumor cells 
after early (3 hpi) or later (24 hpi) addition of the prodrug 5-FC. 0.1 mM 5-FC was added 
either at 3 hpi (bars to the left) or at 24 hpi (bars to the right) and incubated for 24, 48, 72, 96 
and 120 h. Remnant tumor cell masses were quantified by SRB assay. Values: mean of three 
independent experiments performed in triplicates. Error bars: SEM. (Yurttas et al, 2014)
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The cell mass in percent of mock treated of both cell lines was 
decreased by infection and prodrug application. It was again possible to 
observe that the longer the incubation period and therefore 5-FC availability, the
more striking the oncolytic effect.
However, when comparing different time points of prodrug addition post 
infection (3 hpi, 24 hpi, 48 hpi and 72 hpi), in case of HCT116, the remaining 
cell mass of those, which were treated with 5-FC at 24 hpi was always the 
lowest. HCT15 showed similar results when 5-FC was present for 24, 48 or 72 
hours. After 96 and 120 hours, addition of 5-FC at 3 hpi led to a lower cell mass 
than any other (Yurttas et al, 2014).
Taken together, 5-FC seems to be most effective when being available 
as long as possible. Moreover, prodrug addition at 24 hpi was found to be most 
effective. When the presence of prodrug was limited to a defined duration, 
addition at 24 hpi seemed to work best. If there is no time restriction to prodrug 
availability, the results imply to apply 5-FC earlier and hence longer (Yurttas et 
al, 2014). 
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3.3. Pulsed application of 5-FC
There were also other options how 5-FC could be administered. One 
approach was to add 5-FC only for a certain period of time and to remove it 
afterwards, so that the tumor cells can proliferate and make themselves 
therefore more susceptible for chemotherapy. Also, periods in which there is no 
5-FU available might support viral spread by not killing too many (progeny virus 
producing) tumor cells in the first place. Possible inhibition of viral replication by 
5-FU could be altered by pulsed applications as well (Yurttas et al, 2014).
To examine single and multiple pulses of 5-FC, HCT116 and HCT15 
tumor cells were treated as described in the following:
single pulses
Figure 3.9. Application scheme for single pulsed prodrug treatment of MeV-SCD infected 
tumor cells. Tumor cells were plated and infected or mock treated the following day. Medium 
with or without 0.1 mM 5-FC was added at 3 hpi or 24 hpi or 48 hpi or 72 hpi and remained for a
defined period of 6 h each. Then, at 144 hpi remaining cells were fixed with TCA. Remnant 
tumor cell masses were quantified by SRB assay.
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multiple pulses
Figure 3.10. Application scheme for multiple pulsed prodrug treatment of MeV-SCD 
infected tumor cells. Tumor cells were plated and infected or mock treated the following day. 
Medium with or without 0.1 mM 5-FC was added (i) at 3, 24, 48, and 72 hpi, (ii) at 24, 48, and 
72 hpi, (iii) at 24 and 72 hpi, or (iv) at 3 and 48 hpi; each 5-FC pulse remained there for a 
defined period of 6 h. Then, at 144 hpi remaining cells were fixed with TCA. Remnant cell 
masses were quantified by SRB assay.
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Figure 3.11. Effect of pulsed prodrug application. Tumor cells were mock treated or infected 
with MeV-SCD at MOI 0.01 or 1, respectively. 
Single pulses (upper panels): medium with or without 0.1 mM 5-FC was added at 3 hpi or 24 
hpi or at 48 hpi or 72 hpi (from left to right) and remained for a defined period of 6 h each. 
Multiple pulses (lower panels): medium with or without 0.1 mM 5-FC was added (i) at 3, 24, 
48, and 72 hpi, (ii) at 24, 48 and 72 hpi, (iii) at 24 and 72 hpi, or (iv) at 3 and 48 hpi; each 5-FC 
pulse remained there for a defined period of 6 h. Then, at 144 hpi remaining cells were fixed 
with TCA. Remnant tumor cell masses were quantified by SRB assay. Values: mean of three 
independent experiments performed in triplicates. Error bars: SEM. (Yurttas et al, 2014)
Similar to the continuous application of 5-FC as described in section 3.3.,
the pulsed application consisted of 6 groups. The four columns of each group 
describe the time points, at which 5-FC has been administered for 6 hours. 
From left to right, single pulses were added at 3 hpi, 24 hpi, 48 hpi or 72 hpi 
respectively. Multiple 6 h pulses were applied at 3 hpi, 24 hpi, 48 hpi and 72 hpi 
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in the first group, in the second at 24 hpi, 48 hpi and 72 hpi. The third group 
received 6 h of 5-FC at 24 hpi and 72 hpi and the fourth at 3 hpi and 48 hpi 
(Yurttas et al, 2014).
  
Mock treated cells in group one were set to 100 %. Viral infections with addition 
of 5-FC free medium showed only slight differences compared to the mock 
treated control. 
Administration of single or multiple pulses of 5-FC to uninfected cells 
caused no measurable effect. Also, single pulses had no effect on HCT116 
tumor cells being infected at MOI 0.001 and 0.01. Even multiple pulses led to 
only little oncolysis. Merely three or four 6 hour-pulses were able to reduce the 
cell mass in the range of about 20 %.
In contrast, HCT15 showed more response. Single pulses applied to 
infected cells (MOI 1) caused a significant tumor cell killing, which was most 
effective with a 6 hours 5-FC pulse applied at 24 hpi. Multiple pulses to MOI 1 
infected HCT15 cells caused even more killing. The effect of four pulses with 
one pulse each at 3 hpi, 24 hpi, 48 hpi, and 72 hpi led to the same result as 
three pulses with one pulse each at 24 hpi, 48 hpi, and 72 hpi or 2 pulses given 
at 24 hpi and 72 hpi. However, two pulses with one being applied at 3 hpi and 
one at 48 hpi was not as effective as the other approaches.
Taken together, 5-FC pulsing for periods of 6 hours did not show any 
advantage in reducing the cell mass compared to a continuous application of 5-
FC, neither single pulses nor multiple pulses with up to four repeats.
3.4. Sensitivity to 5-FU
To compare single treatment with 5-FU to armed virotherapy with
prodrug addition, all tumor cell lines were tested for their sensitivity to the 
chemotherapeutic drug. Therefore, ascending concentrations from 10-6 to 1 mM 
5-FU were administered for 72 h, 96 h and 120 h (Yurttas et al, 2014). 
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Figure 3.12. Time and dose dependent effects of 5-FU on tumor viabilities. Tumor cells 
were mock treated or with rising concentrations of 5-FU (10-6 - 1 mM, from left to right) and 
incubated for defined time periods of 72, 96 and 120 h. Remaining tumor cell masses were 
determined by SRB assays. Values: mean of three independent experiments performed in 
triplicates. Error bars: SEM.
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Figure 3.13. Time and dose dependent effects of 5-FU on tumor cell viabilities. Tumor 
cells were mock treated or with rising concentrations of 5-FU (10-6 - 1 mM, from left to right) 
and incubated for defined time periods of 72, 96 and 120 h. Remaining tumor cell masses 
were determined by SRB assays. Values: mean of three independent experiments performed 
in triplicates. Error bars: SEM. (Yurttas et al, 2014)
In general, concentrations up to 10-4 mM 5-FU only had little or even no 
effect at all. After 72 h of treatment with 10-3 mM, tumor cell lines COLO205, 
HCC2998, KM12 and HuCCT-1 began to respond to the drug. For cell lines 
Hep3B, it took 96 h of incubation with 10-3 mM 5-FU to cause an effect and 120 
h for HT29 and SW620. When adding 5-FU in a concentration of 10-2 mM for 72 
h, a reduction of cell mass was visible in all cell lines. However, not all of them 
could be killed more efficiently by extending the duration of treatment 
significantly. This was for example the case for HCT116 and HCT15. In 
contrast, all other cell lines did react to a prolongation. By all means, higher 
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concentrations enhanced cytotoxicity so that 1 mM 5-FU killed tumor cells 
almost completely (Yurttas et al, 2014). 
In the following table, for each tumor cell line and for each duration of 5-
FU treatment, the lowest concentration of 5-FU is given, which was able to 
reduce the tumor cell mass to less than 50 %.
61
Results
Table 3.2. Results of the dose and time dependent effect of 5-FU on tumor cell viability. 
Shown are the concentrations of 5-FU causing a tumor cell mass reduction of > 50 % when 
appended for the durations of time given at the top of each column. 5-FU = 5-fluorouracil, mM = 
milimolar, h = hours.
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3.5. Virus growth curves
The cytostatic compound 5-FU possibly not only kills tumor cells, but also
could have an influence on viral replication. In order to investigate whether the 
converted prodrug might inhibit virus production, viral growth curves were 
performed with cell lines HCT116, HCT15, Hep3B and HuCCT-1. Cells were 
infected with MOIs of 0.03 and 0.3 respectively and 0.1 mM 5-FC or medium 
without 5-FC was added at 3 hpi or 24 hpi (Yurttas et al, 2014). 
The following application scheme explains how the experiment was 
performed in detail.
Fig 3.14. Application and harvesting scheme for virus growth curves of MeV-SCD with 
prodrug addition. Tumor cells were plated and infected the following day. Additional medium 
with or without 0.1 mM 5-FC was added at 3 hpi or at 24 hpi and remained there until sample 
taking. Samples of supernatant and Opti-MEM dissolved lysate were taken at the time points 
shown below the time bar.
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Figure 3.15. Virus growth behavior in dependence of prodrug 5-FC incubation onset and 
duration. Cells were infected with MeV-SCD at MOI 0.03 (HCT116, Hep3B, HuCCT-1) or 0.3 
(HCT15), respectively. Additional medium with or without 0.1 mM 5-FC was added at 3 hpi or at 
24 hpi and remained until the end of the experiment at 144 hpi. At 24, 48, 72, 96, 120, and 144 
hpi, samples of supernatants and cell lysates were taken and analysed by titration on Vero cells
for quantification of the amounts of newly produced progeny virus particles. FFU = fluorescence 
forming units. Values: mean of three independent experiments. Error bars: SEM. (Yurttas et al, 
2014)
In all approaches, virus concentration increased in the first 48 hours, in 
supernatants as well as in the cell lysates. 
With regard to results from HCT116, the titer reached a maximum of 
more than 104 pfu / ml in the supernatant and lysate without addition of 5-FC. 
Hereon after, the titer constantly decreased. Compared to the results in the 
presence of prodrug, the concentration was partly 10- to 100-fold higher. 
Whereas the addition of 5-FC at 3 hpi led to lower titers from 24 hpi on, 5-FC 
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addition at 24 hpi caused a virus reduction at 48 hpi. In general, the 
concentrations of infectious virus particles being detected within the supernatant
and in tumor cell lysates were found to be similar (Yurttas et al, 2014).
In contrast, viral titers in the supernatant in all approaches with HCT15 
were constantly about 10-fold lower than those in cell lysates. Without addition 
of 5-FC, the concentrations reached a maximum of 103 pfu / ml in the lysate and
102 pfu / ml in the supernatant at 48 hpi and later on were found to decrease. 
The addition of the prodrug at 3 hpi resulted in quite similar viral titers, except 
for the maximum at 72 hpi and a less abrupt drop then on. The highest viral 
titers at 48 hpi were reached when 5-FC was added at 24 hpi, consequently 
ending up in comparable titers to the approach with prodrug addition 3 hpi.
The highest viral titers overall were reached with the tumor cell line 
Hep3B without addition of 5-FC. The titer constantly increased to a maximum of
106 pfu / ml in both, supernatant and lysate at 144 hpi. Although the 
concentration was about 10-fold lower in all supernatant samples before 144 
hpi, final data/yields were found to be almost identical. In combination with 5-
FC, regardless of addition at 3 or 24 hpi, the titer was always lower than 104 
pfu / ml. Concentration within the tumor cell lysate temporarily reached a 
maximum of 104 pfu / ml at 72 hpi and subsequently decreased. Titers in the 
supernatants were about 10- to 100-fold lower at early time points (24 hpi, 48 
hpi, and 72 hpi), but converged at later time points (Yurttas et al, 2014).
Viral growth curves of HuCCT-1 were all found to be quite similar. 
Addition of 5-FC, whether at 3 or at 24 hpi, had no obvious effect on the titer 
compared to the approach without 5-FC application. Besides, the curves of 
supernatant and cell lysate are almost identical in all growth curves from 
HuCCT-1 (Yurttas et al, 2014).
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3.6. Summary
Taken together, a continuous and early application of 5-FC was found to 
be most effectively enhancing the oncolytic effect, especially when compared to
an intermittent treatment. This was despite the observation, that the prodrug 
addition caused an inhibitory effect on the generation of infectious progeny virus
particles.
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4. Discussion
Oncolytic virotherapy is a novel approach for the therapy of cancer. The 
employed viruses selectively infect and replicate in tumor cells and have 
therefore no effect on non-malignant cells (Russell et al, 2007). Measles 
vaccine virus also meets with these criteria (Msaouel et al, 2009). However, 
virotherapy when given alone has been shown to be mostly insufficient so far, 
so that current treatment modalities have to be improved (Liu et al, 2006). There
are many approaches to enhance the oncolytic effect of administered viruses. 
One is based on the suicide gene therapy technology, which employs one or 
more viral, bacterial or fungal genes which allow the conversion of non-toxic 
compounds (prodrugs) into lethal drugs when being encoded in the respective 
virus genome (Lal et al, 2000). Due to the selective infection of tumor cells, the 
toxification only takes place within infected tumor cells (Cattaneo et al, 2008). 
Although suicide gene therapy has been used in the context of solid tumors in a
large number of preclinical and also some clinical studies (mostly employing 
adenoviral or vaccinia virotherapeutics in solid cancer patients such as 
NCT00415454, NCT00583492, NCT00844623, NCT00964756 and 
NCT00978107), its application to cancer patients so far has not reached any 
clinical significance (Duarte et al, 2012). 
One of the current limitations can be referred to the missing knowledge 
on how to optimally apply the respective prodrugs following application of viro-
therapeutic vectors encoding distinct suicide genes. Of note, when looking at 
the literature, there are not many investigations so far which aim at dissecting 
which timing of prodrug addition would be optimal in an in vivo setting or in a 
clinical trial when making use of a vector encoded suicide gene function by 
systemic application of a respective prodrug. However, in order to design a 
clinical study employing MeV-SCD, an effective dosing scheme for prodrug 5-
FC is required and also claimed by German authorities (Paul-Ehrlich Institute, 
Langen, Germany). Therefore, the aim was to investigate and compare different
prodrug application schemes for the treatment of MeV-SCD infected tumor cells
and to determine the most effective one. 
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Accordingly, this in vitro study has set out to provide a systematic data 
basis for the design of potential future prodrug application regimens, focussing 
on the time for our prototypic measles vaccine virus vector MeV-SCD which 
encodes a suicide fusion protein consisting of CD and UPRT (Erbs et al, 2000; 
Berchtold et al, 2013). Notably, we particularly looked for potential interferences
of the prodrug being enzymatically converted into nucleoside analogs thereby 
potentially impairing virotherapeutic replication.
From the sketch book, there are several possibilities for the design of 
clinical prodrug application regimens: (i) to start with the prodrug application 
quite early after the application of the virotherapeutic vector, or (ii) to first let the 
virotherapeutic vectors replicate for a defined time span before initiating a 
prodrug-mediated enhanced killing of tumor cells (which unavoidably includes 
killing of vector producing tumor cells), (iii) to apply the prodrug continuously 
intravenously, thereby being able to ensure constant plasma levels of the pro-
drug over time, or (iv) to apply the prodrug repeatedly orally, mostly resulting in 
a noncontinuous plasma level of the prodrug (e.g., due to permanent renal 
elimination of the prodrug).
In order to simulate these scenarios in vitro, we initiated application of the pro-
drug 5-FC at different time points post infection and we either let the prodrug 
remain in the tumor cell culture medium continuously for different time spans 
(“continuous” 5-FC application) or applied it temporarily for defined shorter 
periods of time (“pulsed” 5-FC application), using changes of the culture 
medium at defined time points (Yurttas et al, 2014).
1. The enhanced oncolytic effect by prodrug addition is dependent on the 
time point and duration of prodrug application
Numerous studies dealt with the enhancement of oncolytic effectiveness 
by arming viruses with prodrug convertases. Especially AdV, HSV, VV and MeV
were equipped with CD, UPRT, CD in combination with UPRT, TK or purine 
nucleoside phosphorylase (PNP). All of these studies reported an improved rate
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of oncolysis both under in vitro and in vivo conditions. At the same time 
however, their results posed the question at which time prodrug addition might 
yield the best anti-tumoral effects.
Wildner et al treated mice bearing s.c. melanoma or cervical carcinoma with an 
armed AdV. Mice received intratumoral injections of AdV-TK, followed by 7 days
of GCV application. Their survival was prolonged significantly, but the outcome 
of GCV addition being initiated at 24 hpi or at 72 hpi differed largely, showing 
that prodrug application beginning at 72 hpi was far more effective (Wildner et 
al, 1999).
Another group studied the ability of AdV, armed with UPRT, to infect and 
replicate in mice xenograft models of peritoneally disseminated biliary cancer. 
Treatment with 5-FU was found to be beneficial when administered 10 or 15 
days after infection. Any earlier addition erased the virus and in consequence 
did not prolong survival. It was thus concluded that prodrug timing is a highly 
crucial factor (Seo et al, 2005).
Similar observations were made by Ungerechts et al, who armed MeV with PNP
to convert fludarabine phosphate into its active metabolite 2-fluoroadenine, 
which interferes with DNA, RNA and protein synthesis. In a lymphoma xenograft
model, MeV-PNP effectively infected tumor cells. Prodrug addition however only
enhanced tumor cell killing when added not too early after infection (< 24 hpi), 
otherwise viral replication and spread were found to be inhibited significantly 
(Ungerechts et al, 2007).
These authors assumed that prodrug addition at the peak of convertase 
expression would be most beneficial. However, in a clinical scenario it would not
be easy to determine the peak of convertase expression in a non-invasive 
manner.
To determine an optimal prodrug application scheme, in this thesis multiple 
tumor cell lines were infected with MeV-SCD and the prodrug 5-FC was added 
at different time points (3 hpi, 24 hpi, 48 hpi or 72 hpi) and remained 
continuously until the end of the experiment at 144 hpi. As a result, this 
experimental setting showed much higher effectiveness the earlier the prodrug 
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was applied (Yurttas et al, 2014). However, it was not possible to ascribe the 
effects to the earlier administration only as prodrug availability differed as well. 
Therefore, it was necessary to examine the conditions separately. Cell lines 
HCT116 and HCT15 were infected and treated with 5-FC from 3 or 24 hpi on 
and incubated for 24, 48, 72, 96 or 120 h. The results of prodrug addition at 3 or
24 hpi but for the same time periods were compared. As a result, incubation 
with 5-FC from 24 hpi on proved to be more effective compared to application 
from 3 hpi on (Yurttas et al, 2014).
A specific investigation of prodrug timing in coordination with viral gene 
expression was also performed by Yamada et al. HSV-1 was armed with pro-
drug convertases CD and UPRT and used to infect human and mouse colon 
cancer cell lines in vitro and in a xenograft mouse colon cancer model. The in 
vitro data showed that tumor cell killing was the more effective the earlier 5-FC 
was administered after infection. 
These data were quite similar to the results of the continuous prodrug 
application in this thesis. The most effective time point for addition of 5-FC was 
found to be the earliest as well (Yurttas et al, 2014). However, in the 
experimental approach of Yamada et al, it was not possible to distinguish 
whether the effect was due to an earlier or longer availability of the prodrug or a 
combination of both. These authors determined tumor cell killing at 5 days post 
infection. In contrast, in this thesis, tumor cell killing was determined at 6 days 
after infection, in order to provide more time for the read out of the different 
effects finally leading to tumor cell killing (i.e. high level replication of the study 
virus in tumor cells as well as suicide gene-mediated effects). 
To separately examine the effect of prodrug addition at different time points in 
this thesis, the incubation period after prodrug application was kept the same. 
With this experimental setting, it became obvious that the increased 
effectiveness was due to a longer, but not to an earlier availability of the prodrug
5-FC. Tumor cell killing after prodrug addition at 24 hpi compared to addition at 
3 hpi was found to be more effective, when comparing the same duration of 
prodrug availability (Yurttas et al, 2014). 
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These results are also in line with the assumption that prodrug conversion is 
most effective when viral gene expression (here: suicide gene expression) is at 
its height.
The in vivo data of Yamada et al confirm this: in the first experimental setting, 5-
FC was added for 6 days at different time points post infection (0 days, 3 days, 
6 days). Inhibition of tumor growth was most effective when 5-FC was added 3 
days post infection. With this finding, the next group was treated for different 
time periods (6, 12 or 18 days) but from the same time point on (3 days post 
infection). Enhanced efficacy was achieved with a period of 12 days, whereas 
longer treatment did not improve the outcome anymore. Consistent with the 
assumption that prodrug treatment should be started when the expression of 
the prodrug convertase is at its peak, viral titers and DNA copy numbers were 
found to be highest on the third day (Yamada et al, 2012).
In this thesis, the most effective time point to start with prodrug treatment was 
found to be at 24 hpi (Yurttas et al, 2014), whereas Yamada et al showed that 
in vivo infection of mouse colon cancer with HSV-CD-UPRT takes 3 days for 
maximal gene expression; therefore, prodrug application was initiated at 3 days 
post virotherapy by these authors.
All these observations indicate that optimal prodrug timing depends on 
the individual setting of employed virus and treated tumor entity, but that pro-
drug application probably yields its maximal effect when administered at the 
peak of prodrug convertase expression (Seo et al, 2005; Ungerechts et al, 
2007; Yamada et al, 2012). 
Hence, future investigations and also clinical trials employing suicide gene 
encoding viruses should consider to monitor viral replication to individually 
determine the maximum of viral gene expression and replication and therefore 
the optimal time point of prodrug administration. Possible approaches could be 
to utilize viruses expressing soluble marker proteins (e.g. MeV-CEA) in addition 
to their prodrug convertase, being then used as surrogate parameters indicating
the optimal time point for prodrug addition.
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2. A pulsed prodrug application did not demonstrate any advantage over a 
continuous prodrug treatment
The idea of a pulsed 5-FC application was to let tumor cells proliferate 
first in the absence of 5-FU (being generated by conversion of the prodrug 5-
FC), so that they could be hit in their highly vulnerable cell cycling phase by 
pulses of high 5-FU concentrations. A bigger percentage of tumor cells was 
therefore thought to be killed. Furthermore, a pulsed prodrug application was 
considered also to possibly enhance viral replication and thus overall 
effectiveness.
To investigate these hypotheses, tumor cell lines HCT116 and HCT15 
were infected with MeV-SCD and 5-FC was administered at different time points
(3 hpi, 24 hpi, 48 hpi or 72 hpi) and remained for a period of 6 hours in the 
culture medium. These prodrug pulses were either appended once or up to four 
times (Yurttas et al, 2014). 
However, the results clearly showed that a pulsed application is not 
superior to an early and continuous prodrug treatment (Yurttas et al, 2014). This
might be due to various reasons: prodrug convertase expressing tumor cells 
were shown to produce far higher 5-FU concentrations after prodrug application
than achievable by systemic 5-FU therapy, thus being unable to elude the effect
of 5-FU (Richard et al, 2007). A pulsed application to ensure proliferation of as 
many cancer cells as possible would therefore not be required to sufficiently kill 
them.
A second reason might be that the 6 hours pulses were too short to achieve the 
necessary effect. It could be investigated, whether pulses of 12 or 24 hours are 
more effective than a continuous application.
Finally, the removal of culture medium after each pulse could lead to the loss of 
a crucial percentage of diluted virus thus decreasing the number of progeny 
viruses and therefore further infectious and oncolytic particles (Yurttas et al, 
2014). 
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Certainly, a continuous prodrug application enhances the oncolytic viro- 
therapy significantly. Chalikonda et al treated human ovarian tumor cells in a 
xenograft model with vaccinia virus, armed with CD. A continuous application of
5-FC enhanced the efficacy at every time point, compared to the infection alone
(Chalikonda et al, 2008).
The effectiveness of continuous prodrug availability was also observed by 
Yamada et al, who showed that HSV-TK persisted for at least 2 weeks intra-
tumorally after infection with a constantly detectable expression of transgenes 
(Yamada et al, 2012). Hence, the continuous expression of prodrug 
convertases could efficiently convert continuously administered prodrugs.
Similar conclusions were drawn by Tai et al and Lu et al. They used a 
replicating retrovirus (RRV) genetically modified to express CD and performed 
infections in a mouse model of HCC. Tumors revealed a long-term persistence 
and stable expression of RRV, indicating that a continuous application of a pro-
drug could result in a continuous conversion of the prodrug over time (Tai et al, 
2010; Lu et al, 2012). Finally, also Foloppe et al were able to detect expression 
of CD up to 30 days in xenograft mouse models of colon cancer after systemic 
delivery of a vaccinia virus encoding CD and UPRT (Foloppe et al, 2008).
Taken together, the stable expression of suicide transgenes after infection and 
the ability to achieve far higher concentrations of converted prodrug within the 
tumor cells support the approach to continuously administer the prodrug. 
Application schedules to assure cellular proliferation or that the majority of cells 
is in a specific phase of the cell cycle are apparently not necessary to 
sufficiently enhance the oncolytic effect. On this basis, the design of future 
clinical trials is made much easier (Yurttas et al, 2014).
3. Prodrug addition enhances oncolysis but has an inhibitory effect on the 
generation of infectious progeny virus particles
The enhanced oncolytic effect by prodrug addition could be confirmed in 
numerous studies and also in this thesis (Yurttas et al, 2014). At the same time 
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however, some authors reported about an inhibitory effect on viral replication by
prodrug conversion.
In this thesis, it was not possible to make a general statement about the 
inhibitory effect of converted 5-FC on viral replication and spread of MeV-SCD. 
In cell lines HCT116 and Hep3B, a decrease in viral titers was obvious, 
whereas in cell lines HCT15 and HuCCT-1 only moderate or even no effects on 
virus replication were visible. It was not clear, whether the virus titers measured 
in HCT116 and Hep3B tumor cells were lower because of (i) a direct inhibition 
of viral replication or because (ii) the prodrug addition enhanced oncolysis and 
therefore withdrew the virus' breeding grounds. In contrast to the first 
assumption, viral titers in HuCCT-1 tumor cells were found to be constant, 
although oncolysis was found to be enhanced by prodrug addition. A production
of 5-FU may therefore be assumed and should have had an influence on viral 
replication, if 5-FU was really inhibitory. What speaks against the second 
hypothesis is that HCT116 tumor cells were killed only moderately after prodrug
addition but showed an obvious drop of viral titers, whereas the cell mass of 
HCT15 tumor cells was reduced to a much larger extent, but concentrations of 
virus were not found to be altered (Yurttas et al, 2014).
To separately investigate whether converted 5-FC has an influence on MeV-
SCD, it would have been necessary to enable viral infection in a host cell in the 
simultaneous presence of 5-FU without lysis of the host cell by neither 5-FU nor
viral replication. 
Seo et al, who used AdV-UPRT and 5-FU for the treatment of disseminated 
biliary cancer, noticed an inhibitory effect on adenoviral expression at even sub-
toxic doses of 5-FU (Seo et al, 2005). In another study, replication of AdV-CD 
was suppressed in melanoma cells when 5-FC was added at 0, 24 or 48 hpi, 
but it could not be decided whether the effect was directly inhibitory on viral 
replication or indirectly by effectively killing the virus host cells (Liu & 
Deisseroth, 2006). The observations were not only restricted to effects of 5-FC 
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prodrug conversion to 5-FU, but also TK-armed AdV titers in glioma models 
were lowered after addition of GCV (Nanda et al, 2001).
Similar results were shown by Bernt et al when administering high doses of 5-
FU (> 0.25 mM) to AdV-CD-UPRT infected colon and cervix carcinoma cells. In 
contrast, they noticed increased viral titers after administration of low 5-FU 
doses (0.25 - 50 µM) to in vitro infected tumor cells and also enhanced viral 
spread in liver metastases after infection and prodrug addition (Bernt et al, 
2002). 
Comparable with the results of Bernt et al, treatment of pancreatic cancer cell 
lines with HSV in combination with 5-FU in vitro increased viral progeny 
production in a dose dependent fashion (1 - 5 µM 5-FU). Possible explanations 
suppose that chemotherapeutic stress makes the host cell more susceptible to 
viral infection and therefore may contribute to increased viral replication 
(Eisenberg et al, 2005).
In contrast to inhibitory effects of prodrug application on AdV, investigations with
HSV-CD (Nakamura et al, 2001) and HSV-CD-UPRT (Simpson et al, 2006; 
Simpson et al, 2012; Yamada et al, 2012) revealed that 5-FC addition directly 
after infection had only minimal effects on viral replication. However, if 
metabolites of converted prodrug 5-FC were added at the time of infection, viral 
replication was found to be suppressed significantly (Simpson et al, 2012). 
These data indicate that the prodrug does not inhibit early HSV replication when
added from the beginning, but that its activated metabolites indeed lower viral 
titers. 
Studies on CD-armed VV were all consistent with the finding that converted 5-
FC, dependent on the dose and expression of prodrug convertase, caused a 
dramatic decrease in replication of vaccinia virus. Observations were made by 
McCart et al, when treating murine colon carcinoma in vitro and in vivo (McCart 
et al, 2000). Similar results were obtained with VV-CD and 5-FC by Chalikonda 
et al and Foloppe et al (Chalikonda et al, 2008; Foloppe et al, 2008). In vitro 
infection of human colon carcinoma cells with VV-CD and treatment with 5-FC 
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directly after infection or at 48 hpi showed that viral titers were decreased 500-
fold, when 5-FC was added directly and 35-fold when administered at 48 hpi 
(Foloppe et al, 2008).
Replication of MeV-PNP was shown to be totally arrested after in vitro infections
of Vero cells, when the prodrug was administered directly after infection and 
lowered 1000-fold when added at 12 or 24 hpi. These results were confirmed by
in vivo experiments: intracranial MeV-PNP administration without prodrug 
addition caused lethal meningoencephalitis in mice, whereas prodrug addition 
from 24 hpi on avoided disease development. It was therefore concluded that 
early prodrug availability could control viral replication and spread (Ungerechts 
et al, 2007). 
It is possible that the inhibitory effect of converted 5-FC on MeV-SCD replication
is not as noticeable as reported in studies with other viruses, because MeV is 
an RNA virus, which could be less affected by the inhibitory effects of 5-FU 
metabolites than DNA viruses (AdV, HSV, VV). In fact, none of the studies 
published so far employed an RNA virus with CD and reported about an 
inhibition of virus replication after prodrug administration.
Combining all those results suggests that numbers of progeny viruses are 
somehow lower, when high concentrations of cyctostatics (such as 5-FU and its
metabolites) are available, whereas relatively low doses could possibly even 
enhance viral replication and spread. This might be due to induced susceptibility
of tumor cells to viral infection and replication (Eisenberg et al, 2005) or to a 
fostering of the release and dissemination of viruses from their host tumor cells 
(Foloppe et al, 2008). Nonetheless, despite the lowered number of viral 
particles, oncolysis is significantly enhanced by high-dose prodrug addition, if 
not applied too early. Ideally, administration starts, when the expression of 
prodrug convertases is at its peak, as any earlier addition could decrease 
infection, replication and suicide gene-expression, thus lowering the 
effectiveness of such suicide gene-armed approaches.
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4. Translating the in vitro study results to potential clinical settings
The findings from the in vitro experiments clearly demand further in vivo 
investigations to determine when and how to ideally administer the prodrug after
virotherapeutic infection. If there is the possibility for a continuous intravenous 
application of 5-FC (here simulated by our “continuous” 5-FC application 
regimens), our results would imply that tumor cell killing is the more efficient the 
longer the overall time span of the 5-FC presence is (Fig. 1); if 5-FC steady-
state plasma levels can be maintained only for limited time spans (maybe due 
to practical reasons) it seems to be preferable to initiate the addition of 5-FC at 
24 hpi and not at 3 hpi (Fig. 2); (2) when applying 5-FC orally (here simulated 
by our 6 hours “ON” pulses of 5-FC), addition of 5-FC at 24 hpi seems to be 
superior over a much earlier application at 3 hpi (Fig. 3) (Yurttas et al, 2014).
So far, there is no full publication on the clinical quantification of concentrations 
of prodrug conversion products (such as 5-FU) in plasma and/or in malignant 
tissues of study patients with solid tumors (Table 1). This for example is true for 
study NCT00415454 (“Phase I Study Combining Replication-Competent 
Adenovirus-Mediated Suicide Gene Therapy With Chemoradiotherapy for the 
Treatment of Non-Metastatic Pancreatic Adenocarcinoma”) in which a single 
intratumoral injection of an adenoviral vector encoding suicide genes CD and 
HSV-TK was followed by a 3 week period of (oral) 5-FC + valganciclovir 
(VGCV) prodrug therapy, which began at 72 hpi. 
In the study “Phase I Trial of Replication-competent Adenovirus-mediated 
Suicide Gene Therapy Combined with IMRT for Prostate Cancer” the same 
adenoviral vector was employed via a single intraprostatic injection on day 1 
(Freytag et al, 2007). Three days later, patients (n=9) were administered 2.6 
weeks (13 days, weekdays only) of 5-FC (150 mg/kg/day; given orally in four 
equally divided doses every 6 hours) and VGCV (1800 mg/day; given orally in 
two equally divided doses every 12 hours) prodrug therapy. As some patients 
(cohort 3 of this study) were scheduled to receive a second adenovirus injection
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on day 22, 13 days rather than 15 days of prodrug application were used in this 
regime to preclude the possibility that the first prodrug therapy cycle would 
inhibit viral replication following the second adenovirus injection (see our own 
discussion above). 
In the subsequent phase II study (n=280) NCT00583492 (“A Randomized, 
Controlled Trial of Replication-Competent Adenovirus-Mediated Suicide Gene 
Therapy in Combination With IMRT Versus IMRT Alone for the Treatment of 
Newly-Diagnosed Prostate Cancer With an Intermediate Risk Profile”) the same
adenoviral vector was employed again via a single intraprostatic injection; in this
case, two days later (day 3), patients received a two week course (10 days, 
weekdays only) of (oral) 5-FC and VGCV prodrug therapy (Lu et al, 2011). 
Unfortunately, neither in the phase I nor in the phase II study was any reporting 
on the determination of concentrations of prodrug conversion products (such as 
5-FU) in plasma and/or in malignant tissues of the study patients exhibiting 
newly-diagnosed prostate cancer. 
In a phase I trial on hepatocellular carcinoma (NCT00844623; “Phase I Clinical 
Trial Of Gene Therapy For Hepatocellular Carcinoma By Intratumoral Injection 
Of TK99UN (An Adenoviral Vector Containing The Thymidine Kinase (TK) Of 
Herpes Simplex Virus”) five consecutive cohorts of two patients received 
increasing doses of an HSV-TK suicide gene encoding adenoviral vector by 
intratumoral injection; subsequently, equal doses of either intravenous GCV or 
oral VGCV were applied; albeit no specific information on dosages or duration 
of prodrug therapies was provided. 
In a further phase I study on ovarian cancer (NCT00964756; “A Phase I Study 
of AD5.SSTR/TK.RGD; A Tropism Modified Adenovirus Vector for Intra-
peritoneal Delivery of Therapeutic Genes and Additional Capability of Non-
invasive Imaging of Gene Transfer in Patients With Recurrent Ovarian and 
Other Selected Gynecologic Cancers (Infectivity Enhanced Adenoviral Vectors 
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for Ovarian CA)”) patients were treated intraperitoneally for 3 days with an HSV-
TK suicide gene encoding adenoviral vector followed by intravenous application
of GCV (5 mg/kg BID; at a constant rate for more than 1 hour) for 14 days (Kim 
et al, 2012). 
In another phase I study in patients with head and neck cancer and other 
malignant tumors, single intratumoral injections of an adenoviral vector 
encoding HSV-TK were performed on day 1 followed by systemic (intravenous) 
administration of GCV (50 mg/kg BID) from days 2 to 15 (Xu et al, 2009). Again,
no data were provided on prodrug plasma levels or prodrug conversion rates.
In a most recent phase I trial, a modified vaccinia virus Ankara vector encoding 
the FCU-1 suicide gene (TG4023) was employed in patients exhibiting primary 
or metastatic unresectable liver tumors via a single intratumoral injection 
followed by a 2-week dosing period of the 5-FC prodrug (200 mg/kg/day; given 
intravenously for the first days (not specified exactly), then orally) 
(NCT0097810). Severe adverse events being related to the application of 5-FC 
were identified as diarrhea, hypertension, and alkaline phosphatase increase. 
Most interestingly, in this study, a first time comprehensive analysis on plasma 
and tumor 5-FC and 5-FU concentrations was performed. As a result, 5-FU 
concentrations were reported to be 56±30 ng/g in tumor biopsies and 1.9± 2.6 
ng/mL in plasma at day 8. Thereby, a first time proof-of-concept of the in vivo 
conversion of the prodrug 5-FC into 5-FU was obtained in liver cancer patients. 
This hallmark clinical study paves the way for further clinical trials employing 
state-of-the-art virotherapeutic vectors armed with potent suicide genes, such 
as MeV-SCD. 
In this context, our own study on “pulsed" versus "continuous" application of the 
prodrug 5-FC for enhancing oncolytic effectiveness of a measles vaccine virus 
armed with a suicide gene is of great help in designing the respective study 
protocols, especially when the timing and duration of the prodrug 5-FC have to 
be fixed (Yurttas et al, 2014).
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5. Summary
Oncolytic virotherapy is a novel approach for the therapy of cancer that 
stems from the observation that tumor patients who simultaneously developed a
viral infection would occasionally experience a complete remission of their 
disease. Meanwhile, different viruses have been preclinically and clinically 
investigated for the treatment of various neoplastic diseases. These viruses are 
characterized by their ability to selectively infect and replicate in tumor cells 
while sparing non-cancerous and normal cells. To further enhance the natural 
and innate oncolytic potency of those viruses, there are approaches to arm 
such viruses by incorporation of therapeutic transgenes via genetical 
modification. 
One such concept is the complementation of the virus genome with the 
genetic sequence of a combinational prodrug-converting enzyme of cytosine 
deaminase and uracil phosphoribosyltransferase (MeV-SCD) that toxifies the 
prodrug 5-FC to the highly potent chemotherapeutic compound 5-FU. The fact 
that tumor cells are infected by virotherapeutics and that the suicide genes of 
the respective virotherapeutics are expressed in tumors selectively enables an 
additional local and highly concentrated chemotherapeutic treatment. Although 
this system has been shown to efficiently enhance the basic virus-mediated 
oncolytic effect, to date optimization of prodrug application schedules has never
been undertaken. 
The aim of this thesis was to utilize a suicide gene-armed measles vaccine
virus for oncolytic virotherapy and to compare different application schemes 
("PULSED" versus "CONTINUOUS") to identify the conditions being required for
an optimal tumor treatment (Yurttas et al, 2014). 
After having chosen suitable amounts of virus for each tumor cell line 
according to the results of an extensive pre-testing, the following treatment 
plans were investigated: 5-FC was applied at different time points after infection
with armed measles vaccine virus and the prodrug remained (i) either 
continuously for different time periods ("continuous" application of 5-FC) or (ii) 
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only temporarily for defined shorter periods ("pulsed" application of 5-FC) in the 
tumor cell culture medium (Yurttas et al, 2014). 
The results clearly indicate that a continuous presence of the prodrug 5-FC
is most effective in terms of the anti-tumoral effect and that this regime is much 
superior to any pulsed application of 5-FC (Yurttas et al, 2014). 
However, prodrug addition was found to exert an inhibitory effect on viral 
replication, but it is yet not clear whether viral titers were lowered by inhibition of
viral replication directly or indirectly by enhancing oncolysis and therefore 
detracting the virus’ host cells (needed for the production of progeny virus 
particles). Despite this inhibitory effect on generating viral progeny particles, an 
early and continuous addition of 5-FC was found to enhance oncolysis 
significantly (Yurttas et al, 2014). 
Knowingly, our experimental in-vitro setting is naturally highly artificial 
and hence not directly convertible to clinical practice. We therefore consider our
results as tentative evidence for designing clinical application regimes with a 
timely defined virotherapeutic treatment of MeV-SCD and the prodrug 5-FC, 
which we plan to hand in to the responsible German authorities (Paul-Ehrlich-
Institute, Langen) for approval. Data of a corresponding clinical phase I study 
will then give further insight into security and antitumor efficiency of this 
innovative and highly promising approach.
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5. Zusammenfassung
Die onkolytische Virotherapie stellt einen neuen Therapieansatz dar, der 
seinen Ursprung in gut dokumentierten Beobachtungen von Krebspatienten hat,
die nach einer sich zufällig zeitgleich zur Tumorerkrankung ereignenden Virus-
infektion eine komplette Remission ihrer Erkrankung erfuhren.
Mittlerweile wurden verschiedene Virusarten präklinisch und klinisch für 
die Behandlung unterschiedlicher Tumorerkrankungen untersucht. Diese Viren 
zeichnen sich durch ihre Eigenschaft aus, Tumorzellen selektiv zu infizieren und
sich in ihnen rasant zu vermehren, was innerhalb kurzer Zeit zu deren virusver-
mittelter Zerstörung (“Onkolyse”) führt. Gesunde Zellen bleiben dagegen unbe-
troffen. Um die onkolytische Wirksamkeit dieser Viren noch zusätzlich zu ver-
bessern, gibt es Ansätze, durch Insertion von Fremdgenen in das Virus-Genom 
(sog. “Armierung”) eine weiter verbesserte Tumorzellabtötung zu erreichen. Ein 
solcher Ansatz kann beispielsweise in der Armierung mit einem Fusionsgen 
bestehen, das für eine Enzymkombination aus Cytosindeaminase und Uracil-
phosphoribosyltransferase (sog. “SCD-Suizidenzym”) kodiert, die das Pro-Phar-
makon (sog. “Prodrug”) 5-FC in das hochpotente Chemotherapeutikum 5-FU 
umwandelt. Die Tatsache, dass die Infektion und Suizidgen-Expression selektiv 
Tumorzellen trifft, ermöglicht somit eine zusätzliche lokale Hochdosis-Chemo-
therapie ohne begleitende sytemische Nebenwirkungen. Obwohl gezeigt wurde,
dass diese Armierungs-Methode den onkolytischen Effekt signifikant verstärkt, 
wurde bisher kein optimales Dosierungsschema auf der Basis einer systemati-
schen Variation der Applikationsbedingungen erarbeitet.
Das Ziel dieser Arbeit war es dementsprechend, Suizidgen-verstärkte 
Masernimpfviren für die onkolytische Virotherapie einzusetzen, verschiedene 
Regime der Pro-Pharmakongabe zu vergleichen und im Resultat ein optimales 
Anwendungsschema zu ermitteln (Yurttas et al, 2014).
Nachdem in einem umfangreichen Vorversuch für jede Tumor-Zelllinie 
eine für Folgeversuche jeweils am besten geeignete Virusmenge ermittelt 
wurde, konnten die entworfenen Behandlungspläne untersucht werden: 5-FC 
wurde zu verschiedenen Zeitpunkten nach der Infektion mit den Suizidgen-ver-
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stärkten Masernimpfviren zugegeben und das Pro-Pharmakon blieb entweder 
kontinuierlich und für unterschiedliche Zeitspannen (kontinuierliche 5-FC Gabe) 
oder nur temporär und für definierte, kurze Zeitspannen (gepulste 5-FC Gabe) 
auf den Tumorzellen. Die Ergebnisse zeigen, dass eine kontinuierliche Pro-
Pharmakongabe die effektivste anti-tumorale Wirkung bewirkt und einer 
gepulsten Applikationsweise deutlich überlegen ist (Yurttas et al, 2014). 
Es wurde jedoch weiterhin festgestellt, dass die Pro-Pharmakonzugabe 
einen unterdrückenden Effekt auf die Virusvermehrung hat. Allerdings ist 
bislang nicht erkenntlich, ob die erniedrigten Virustiter unter Einwirkung von 5-
FC durch direkte Hemmung der Virusvermehrung oder indirekt durch die 
verstärkte Onkolyse und damit durch den Entzug von Wirtszellmasse für das 
Virus zustande kommt. Interessanterweise zeigte eine frühe und kontinuierliche 
5-FC Zugabe trotz des blockierenden Effekts auf die Bildung von 
Virusnachkommen eine signifikante Verstärkung des onkolytischen Effekts 
(Yurttas et al, 2014).
Unser experimenteller in vitro-Ansatz ist wohlwissend von Natur aus sehr
künstlich und damit nicht direkt auf die klinische Anwendung übertragbar. Wir 
betrachten unsere Ergebnisse daher als vorläufige Anhaltspunkte, um 
nachfolgend in Kooperation mit einem Sponsor aus der biopharmazeutischen 
Industrie ein entsprechendes klinisches Anwendungsregime mit zeitlich optimal 
getakteter Behandlung mit unserem Virotherapeutikum MeV-SCD und dem 
Prodrug-Medikament 5-FC zu erarbeiten. Wir planen außerdem, dieses der 
zuständigen Bundesoberbehörde (Paul-Ehrlich-Institut) zur Genehmigung 
vorzulegen. Die Daten einer entsprechenden ersten klinischen Phase I-Studie 
werden dann weiteren Aufschluss über Sicherheit und anti-tumorale Effizienz 
dieses sehr vielversprechenden Ansatzes erbringen.
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5. Perspectives 
Oncolytic virotherapy with measles vaccine virus has already been 
proved to be safe and efficient. Insufficient virotherapeutic approaches can be 
enhanced by arming with a prodrug-converting enzyme. This thesis aimed to 
investigate and compare different prodrug application schemes to identify an 
optimal treatment plan for the novel approach of suicide gene-enhanced 
virotherapy.
Following infection of tumor cells with our prototypic suicide gene-enhanced 
vector MeV-SCD (European patent EP2605783 granted for MeV-SCD on 2015-
03-25), it could be shown that a continuous and long-term availability of 5-FC 
yields superior oncolytic effects compared to any pulsed application of 5-FC. 
Further studies with cell lines of other tumor entities could be performed in the 
same way to investigate whether these findings are conferrable also to other 
solid tumors. Additionally, to also gather further data on patterns of in vivo bio-
distribution, a suitable xenograft model should be chosen to examine and, if 
applicable, confirm these data.
With reference to the assumption of other authors that prodrug addition might 
be most effective when applied at the peak of converting-enzyme (here: SCD) 
expression, an appropriate method to track virus replication and spread should 
be utilized. One possible approach would be to use a modified MeV vector that 
expresses soluble marker proteins (e.g. MeV-CEA) or a radionuclide trans-
porting protein (e.g. MeV-NIS) to adjust timing of prodrug addition with viral 
spread and suicide gene expression (termed as “peak replication guided suicide
gene virotherapy”).
Although the pulsed application of 5-FC did not show any advantage over a 
continuous treatment (Yurttas et al, 2014), the application scheme could be 
varied and other conditions investigated. A prolonged pulse-period of 12 or 24 
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hours might have a beneficial effect. Quantities of multiple pulses could also be 
increased.
Growth curves indicated that prodrug addition and conversion had an inhibitory 
effect on the generation of viral progenies (Yurttas et al, 2014). However, it was 
not evident, whether this was due to a direct or indirect suppression of virus 
growth. It would hence be important to make these possibilities distinguishable. 
A possible yet difficult approach would be to infect a tumor cell line, which is 
resistant to both viral oncolysis and the cytostatic effects of 5-FU, but allows 
viral replication and gene expression. Addition of 5-FC in such a scenario then 
could help to read out its specific influence on viral replication.
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6. Appendix
6.1. Abbreviations
5-FC 5-fluorocytosine
5-FdUDP 5-fluoro-2'-deoxyuridine-5'-diphosphate
5-FdUMP 5-fluoro-2'-deoxyuridine-5'-monophosphate
5-FdUTP 5-fluoro-2'-deoxyuridine-5'-triphosphate
5-FU 5-fluorouracil
5-FUDP 5-fluorouridine-5'-diphosphate
5-FUMP 5-fluorouridine-5'-monophosphate
5-FUTP 5-fluorouridine-5'-triphosphate 
ACV aciclovir
AdV adenovirus
AIDS acquired immune deficiency syndrome
CD cytosine deaminase
CEA carcinoembryonic antigen
CPA cyclophosphamide
CRC colorectal cancer
CTCL cutaneous T-cell lymphoma
DMEM Dulbecco’s Modified Eagle Medium
DMSO dimethylesulfoxide
EDTA ethylendiamintetraacetate
F-Protein fusion protein
FCS fetal calf serum
FFU fluorescence forming units
GCV ganciclovir
HBV hepatitis B virus
HCC hepatocellular carcinoma
HCV hepatitis C virus
hpi hours post infection
H-Protein hemagglutinin protein
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HSV herpes simplex virus
ICTV International Committee on Taxonomy of Viruses 
IFN interferon
GM-CSF granulocyte macrophage colony-stimulating factor
HPLC high-performance liquid chromatography
IJA idiopathic juvenile arthritis
ITP idiopathic thrombocytopenic purpura 
L-Protein large protein
M-Protein matrix protein
MeV measles virus
MeV-CEA measles virus expressing carcinoembryonic antigen
MeV-Edm measles virus Edmonston strain
MeV-SCD measles virus expressing super cytosine deaminase
MOI multiplicity of infection
NASH non-alcoholic steatohepatitis
NIS sodium jodid symporter
NK cells natural killer cells
N-Protein nucleoprotein
OPRT orotate phosphoribosyltransferase
P-Protein phosphoprotein
PBS phosphate buffered saline
PFA paraformaldehyde
RNA ribonucleoacid
RNP ribonucleoparticle
rpm rounds per minute
RPMI Rosswell Park Memorial Institute
RRV replicating retrovirus
SCD super cytosine deaminase
SLAM signaling lymphocyte activation molecule
SRB sulforhodamine B
SSPE subacute sclerosing panencephalitis
TBS TRIS-buffered saline
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TCA trichloroacetate
TRIS tris(hydroxymethyl)-aminomethane
TS thymidylate synthase
UMP uracil monophosphate
uPAR urokinase-type plasminogen activator receptor
UPRT uracil phosphoribosyltransferase
VGCV valganciclovir
VEGF vascular endothelial growth-factor
VSV vesicular stomatitis virus
VV vaccinia virus
WHO World Health Organization
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